UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
For the transition period from to
Commission File No.
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices, including zip code)
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No
As of November 13, 2026 there were
CERO THERAPEUTICS HOLDINGS, INC.
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2026
TABLE OF CONTENTS
| i |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development (“R&D”) costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about:
| ● | our financial performance; |
| ● | our ability to obtain additional cash and the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements, including the development and, if approved, commercialization of our product candidates; |
| ● | the impact of the delisting of our common stock and public warrants from Nasdaq; |
| ● | the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; |
| ● | the scope, progress, results and costs of developing CER-1236 or any other product candidates we may develop, and conducting preclinical studies and clinical trials; |
| ● | the timing and costs involved in obtaining and maintaining regulatory approval of CER-1236 or any other product candidates we may develop, and the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations or accelerated approvals for our drug candidates for various indications; |
| ● | current and future agreements with third parties in connection with the development and commercialization of CER-1236 or any other future product candidate; |
| ● | our ability to advance product candidates into and successfully complete clinical trials; |
| ● | the ability of our clinical trials to demonstrate the safety and efficacy of CER-1236 and any other product candidates we may develop, and other positive results; |
| ● | the size and growth potential of the markets for our product candidates, and our ability to serve those markets; |
| ● | the benefits of orphan drug designation and potential for orphan drug exclusivity in the future for CER-1236 and any other product candidates that may receive orphan drug designation; |
| ● | our plans relating to the commercialization of CER-1236 and any other product candidates we may develop, if approved, including the geographic areas of focus and our ability to grow a sales team; |
| ● | the success of competing drugs, therapies or other products that are or may become available; |
| ● | developments relating to our competitors and our industry, including competing product candidates and therapies; |
| ii |
| ● | our plans relating to the further development and manufacturing of CER-1236 and any other product candidates we may develop, including additional indications that we may pursue for CER-1236 or other product candidates; |
| ● | existing regulations and regulatory developments in the United States and other jurisdictions; |
| ● | our potential and ability to successfully manufacture and supply CER-1236 and any other product candidates we may develop for clinical trials and for commercial use, if approved; |
| ● | the rate and degree of market acceptance of CER-1236 and any other product candidates we may develop, as well as the pricing and reimbursement of CER-1236 and any other product candidates we may develop, if approved; |
| ● | our expectations regarding our ability to obtain, maintain, protect and enforce intellectual property protection for CER-1236 and for any other product candidate; |
| ● | our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of third parties; |
| ● | our ability to realize the anticipated benefits of any strategic transactions; |
| ● | our ability to attract and retain the continued service of our key personnel and to identify, hire, and then retain additional qualified personnel and our ability to attract additional collaborators with development, regulatory and commercialization expertise; |
| ● | our ability to maintain proper and effective internal controls; |
| ● | the impact of macroeconomic conditions and geopolitical turmoil on our business and operations, including interest rates, inflationary pressures, capital market disruptions, changes in governmental agencies, international tariffs, trade protection measures, global conflicts, economic sanctions and economic slowdowns or recessions; |
| ● | our expectations regarding the period during which we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and as a smaller reporting company under the federal securities laws; and |
| ● | our anticipated use of our existing cash and cash equivalents. |
We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions described in “Risk Factors” and elsewhere in this Quarterly Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this Quarterly Report, whether as a result of any new information, future events or otherwise.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.
This Quarterly Report includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this Quarterly Report appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.
Unless the context otherwise requires, all references herein to “we,” “us,” “our” or “the Company” refer to the business and operations of CERo Therapeutics Holdings, Inc. (“CERo”) and its subsidiaries.
| iii |
SELECTED DEFINITIONS
As used in this Quarterly Report, unless otherwise noted or the context otherwise requires, references to the following capitalized terms have the meanings set forth below:
“2016 Plan” refers to the CERo Therapeutics, Inc. 2016 Equity Incentive Plan, as amended from time to time.
“2024 ESPP” refers to the CERo Therapeutics Holdings, Inc. 2024 Employee Stock Purchase Plan, as amended from time to time.
“2024 Plan” refers to the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan, as amended from time to time.
“Arena” refers to Arena Business Solutions Global SPC II, Ltd. on behalf of and for the account of Segregated Portfolio #13 - SPC #13.
“Arena Commitment Shares” refer to up to 500 shares of Common Stock issued to Arena as consideration for executing and delivering the Arena Purchase Agreement.
“Arena Purchase Agreement” refers to the Purchase Agreement, dated as of February 23, 2024, by and between CERo and Arena.
“Board of directors” refers to the board of directors of CERo.
“Business Combination” or “Merger” refers to the transactions contemplated by the Business Combination Agreement, including the merger between Merger Sub and Legacy CERo.
“Business Combination Agreement” refers to the Business Combination Agreement, dated as of June 4, 2023, as amended by Amendment No. 1, dated February 5, 2024 and Amendment No. 2, dated February 13, 2024, by and between PBAX, Merger Sub and Legacy CERo.
“Bylaws” refers to the Second Amended and Restated Bylaws of CERo.
“CERo” refers to CERo Therapeutics Holdings, Inc.
“Charter” refers to CERo’s Second Amended and Restated Certificate of Incorporation, as filed with the Secretary of the State of Delaware February 14, 2024, as amended from time to time.
“Closing” refers to the closing of the Business Combination.
“Commitment Shares” refers to the Arena Commitment Shares and the Keystone Commitment Shares.
“Common Stock” refers to the common stock, par value $0.0001 per share, of CERo.
“Common Warrants” refers to the Public Warrants, Private Placement Warrants, the Conversion Warrants, the Series A Warrants, the Series C Warrants, the December 2024 Common Warrants, the January 2025 Common Warrants, the February 2025 Common Warrants and the February 2025 Pre-Funded Warrants.
“Conversion Warrants” refer to the warrants initially issued by CERo Therapeutics, Inc. and converted into warrants to purchase Common Stock in connection with the Business Combination.
“Convertible Notes” refer to the convertible promissory notes issued to Keystone on February 9, 2026, March 6, 2026, April 8, 2026, and April 27, 2026 and convertible promissory notes issued to SRX Global Inc. (f/k/a SRX Health Solutions Inc) on May 28, 2026, June 23, 2026, July 14, 2026 and August 11, 2026.
| iv |
“December 2024 Common Warrants” refer to the warrants to purchase shares of Common Stock, at a current exercise price of $112.20 per share, issued by the Company in a private placement on December 23, 2024.
“DGCL” refers to the Delaware General Corporation Law, as may be amended from time to time.
“Earnout Shares” refer to the Primary Earnout Shares, the Secondary Earnout Shares and the Tertiary Earnout Shares, collectively.
“Exchange Act” refers to the Securities Exchange Act of 1934, as amended.
“FDA” refers to the U.S. Food and Drug Administration, or any successor agency thereto.
“February 2024 Keystone Purchase Agreement” refers to the Common Stock Purchase Agreement, dated as of February 14, 2024, by and between CERo and Keystone.
“February 2024 Keystone Registration Rights Agreement” refers to the Registration Rights Agreement, dated as of February 14, 2024, by and between CERo and Keystone.
“February 2025 Common Warrants” refer to the warrants to purchase shares of Common Stock, at a current exercise price of $39.20 per share, issued by the Company in a public offering on February 7, 2025.
“February 2025 Pre-Funded Warrants” refer to the warrants to purchase shares of Common Stock, at an exercise price of $0.002 per Share, issued in a public offering on February 7, 2025.
“Fee Modification Agreements” refers to the fee modification agreements between CERo and certain third-party vendors and service providers, pursuant to which such vendors received shares of Common Stock in lieu of certain payments due to such vendors prior to Closing.
“Fifth PIPE Financing” refers to the private placement pursuant to which we issued and sold, and the PIPE Investors purchased, shares of Series E Preferred Stock, on the terms and conditions set forth in the Fifth Securities Purchase Agreement.
“Fifth PIPE Registration Rights Agreement” refers to the Registration Rights Agreement, dated as of October 14, 2025, by and between CERo and certain PIPE Investors.
“Fifth Securities Purchase Agreement” refers to the Securities Purchase Agreement, dated as of October 14, 2025, by and among CERo and certain PIPE Investors, pursuant to which CERo agreed to issue and sell up to 9,750 shares of Series E Preferred Stock.
“First PIPE Financing” refers to the private placement pursuant to which we issued and sold, and the PIPE Investors purchased, shares of Series A Preferred Stock, the Series A Warrants and Preferred Warrants, on the terms and conditions set forth in the First Securities Purchase Agreement.
“First PIPE Registration Rights Agreement” refers to the Registration Rights Agreement, dated as of February 14, 2024, by and between CERo and certain PIPE Investors.
“First Securities Purchase Agreement” refers to the Amended and Restated Securities Purchase Agreement, dated as of February 14, 2024, by and among PBAX, Legacy CERo and certain PIPE Investors, pursuant to which CERo agreed to issue and sell 10,089 shares of Series A Preferred Stock, 306 Series A Warrants and 2,500 Preferred Warrants.
“Fourth PIPE Financing” refers to the private placement pursuant to which we issued and sold, and the PIPE Investors purchased, shares of Series D Preferred Stock, on the terms and conditions set forth in the Fourth Securities Purchase Agreement.
“Fourth PIPE Registration Rights Agreement” refers to the Registration Rights Agreement, dated as of April 22, 2025, by and between CERo and certain PIPE Investors.
| v |
“Fourth Securities Purchase Agreement” refers to the Securities Purchase Agreement, dated as of April 21, 2025, as amended as of June 25, 2025, by and among CERo and certain PIPE Investors, pursuant to which CERo agreed to issue and sell up to 10,000 shares of Series D Preferred Stock.
“Initial Public Offering” refers to the initial public offering of PBAX, which closed on October 8, 2021.
“Investor Rights Agreement” refers to the Investor Rights and Lock-up Agreement, dated February 14, 2024, by and among CERo, the Sponsor, certain Legacy CERo Stockholders and certain other parties.
“January 2025 Common Warrants” refer to the warrants to purchase shares of Common Stock, at a current exercise price of $116.40 per share, issued by the Company in a private placement on January 6, 2025.
“July 2025 Keystone Purchase Agreement” refers to the Common Stock Purchase Agreement, dated as of July 11, 2025, by and between CERo and Keystone.
“July 2025 Keystone Registration Rights Agreement” refers to the Registration Rights Agreement, dated as of July 11, 2025, by and between CERo and Keystone.
“Keystone” refers to Keystone Capital Partners, LLC.
“Keystone Commencement Date” refers to the time when all of the conditions to our right to commence sales of Common Stock to Keystone set forth in the respective Keystone Purchase Agreements have been satisfied.
“Keystone Commitment Amount” refers to the $25,000,000 of shares of Common Stock that Keystone has committed to purchase pursuant to the Keystone Purchase Agreements.
“Keystone Commitment Shares” refers to the 992 shares of Common Stock that have been issued to Keystone as consideration for Keystone entering into the Keystone Purchase Agreements.
“Keystone Equity Financing” refers to the equity line of credit established by the Keystone Purchase Agreements.
“Keystone Purchase Agreements” refers to the February 2024 Keystone Purchase Agreement, November 2024 Keystone Purchase Agreement, July 2025 Keystone Purchase Agreement and the November 2025 Keystone Purchase Agreement.
“Keystone Purchase Shares” refers to the shares of Common Stock that CERo may elect to issue and sell to Keystone after the Keystone Commencement Date.
“Keystone Registration Rights Agreements” refers to the February 2024 Registration Rights Agreement, November 2024 Registration Rights Agreement, July 2025 Keystone Registration Rights Agreement and the November 2025 Keystone Registration Rights Agreement.
“Legacy CERo” refers to CERo Therapeutics, Inc.
“Legacy CERo common stock” refers to the common stock, par value $0.0001 per share, of Legacy CERo.
“Legacy CERo preferred stock” refers to the preferred stock, par value $0.0001 per share, of Legacy CERo.
“Legacy CERo Stockholders” refers to the holders of Legacy CERo common stock and/or Legacy CERo preferred stock prior to the Business Combination.
“Legacy CERo warrants” refers to the warrants to purchase shares of Legacy CERo preferred stock.
| vi |
“Liquidated Damages Modification Agreement” refers to the Liquidated Damages Modification Agreement, dated as of February 23, 2024, by and between us and Danforth Advisors, LLC.
“Merger Sub” refers to PBCE Merger Sub, Inc., a Delaware corporation.
“Nasdaq” refers to the Nasdaq Stock Market LLC.
“November 2025 Keystone Purchase Agreement” refers to the Common Stock Purchase Agreement, dated as of November 26, 2025, by and between CERo and Keystone.
“November 2025 Keystone Registration Rights Agreement” refers to the Registration Rights Agreement, dated as of November 26, 2025, by and between CERo and Keystone.
“November 2024 Keystone Purchase Agreement” refers to the Common Stock Purchase Agreement, dated as of November 8, 2024, by and between CERo and Keystone.
“November 2024 Keystone Registration Rights Agreement” refers to the Registration Rights Agreement, dated as of November 8, 2024, by and between CERo and Keystone.
“PBAX” refers to Phoenix Biotech Acquisition Corp., a Delaware corporation.
“PIPE Financings” refers to the First PIPE Financing, the Second PIPE Financing, the Third PIPE Financing, the Fourth PIPE Financing and the Fifth PIPE Financing.
“PIPE Investors” refer to the investors in the PIPE Financings.
“PIPE Registration Rights Agreement” refers to the First PIPE Registration Rights Agreement, the Second PIPE Registration Rights Agreement, the Third PIPE Registration Rights Agreement, the Fourth PIPE Registration Rights Agreement and the Fifth PIPE Registration Rights Agreement.
“PIPE Warrants” refer to the Series A Warrants, the Series C Warrants and the Preferred Warrants issued in the PIPE Financings.
“Preferred Stock” refers to the shares of preferred stock, par value $0.0001 per share, of CERo.
“Preferred Shares” refer to the shares of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock issued in the PIPE Financings, including the Warrant Preferred Shares.
“Preferred Warrants” refer to warrants to purchase shares of Series A Preferred Stock.
“Primary Earnout Shares” refer to the 600 shares of Common Stock issued to the holders of Legacy CERo common stock and Legacy CERo preferred stock in connection with the Business Combination, 500 of which are subject to vesting upon the achievement of certain stock price-based earnout targets and 100 of which are subject to vesting upon a change of control, respectively.
| vii |
“Private Placement Warrants” refer to private placement warrants to purchase shares of Common Stock, at an exercise price of $23,000.00 per share, that were originally sold in a private placement concurrently with the Initial Public Offering.
“Public Warrants” refer to the warrants to purchase shares of Common Stock, at an exercise price of $23,000.00 per share, that were originally issued in the Initial Public Offering.
“Reverse Stock Splits” refers to the Company’s reverse stock split that became effective at 12:01 a.m. Eastern time on January 8, 2025, pursuant to which each 100 shares of Common Stock outstanding immediately prior thereto was converted into 1 share of Common Stock outstanding immediately thereafter, and to the Company’s reverse stock split that became effective at 12:01 a.m. Eastern time on June 13, 2025, pursuant to which each 20 shares of Common Stock outstanding immediately prior thereto was converted into 1 share of Common Stock outstanding immediately thereafter.
“SEC” refers to the U.S. Securities and Exchange Commission.
“Secondary Earnout Shares” refer to the 438 shares of Common Stock issued to the holders of Legacy CERo common stock and Legacy CERo preferred stock in connection with the Business Combination, which became fully vested at Closing.
“Second PIPE Financing” refers to the private placement pursuant to which we issued and sold, and the PIPE Investors purchased, shares of Series B Preferred Stock, on the terms and conditions set forth in the Second Securities Purchase Agreement.
“Second PIPE Registration Rights Agreement” refers to the Registration Rights Agreement, dated as of March 29, 2024, by and between CERo and certain PIPE Investors.
“Second Securities Purchase Agreement” refers to the Securities Purchase Agreement, dated as of March 29, 2024, by and among CERo and certain PIPE Investors, pursuant to which CERo agreed to issue and sell 626 shares of Series B Preferred Stock.
“Securities Act” refers to the Securities Act of 1933, as amended.
“Securities Purchase Agreements” refers to the First Securities Purchase Agreement, the Second Securities Purchase Agreement, the Third Securities Purchase Agreement, the Fourth Securities Purchase Agreement and the Fifth Securities Purchase Agreement.
“Selling Securityholder” refers to Keystone.
“Series A Certificate of Designations” refers to the Certificate of Designations of Rights and Preferences of the Series A Preferred Stock, as amended from time to time.
“Series A Preferred Stock” refers to the Series A convertible preferred stock, $0.0001 par value per share, of CERo.
“Series A Warrants” refers to warrants to purchase Common Stock, at a current exercise price of $2,780.00 per share, sold to certain PIPE Investors pursuant to the First Securities Purchase Agreement.
“Series B Certificate of Designations” refers to the Certificate of Designations of Rights and Preferences of the Series B Preferred Stock, as amended from time to time.
“Series B Preferred Stock” refers to the Series B convertible preferred stock, $0.0001 par value per share, of CERo.
“Series C Certificate of Designations” refers to the Certificate of Designations of Rights and Preferences of the Series C Preferred Stock, as amended from time to time.
“Series C Preferred Stock” refers to the Series C convertible preferred stock, $0.0001 par value per share, of CERo.
| viii |
“Series C Warrants” refers to warrants to purchase shares of Common Stock, at a current exercise price of $0.80 per share, sold to certain PIPE Investors pursuant to the Third Securities Purchase Agreement.
“Series D Certificate of Designations” refers to the Certificate of Designations of Rights and Preferences of the Series D Preferred Stock, as amended from time to time.
“Series D Preferred Stock” refers to the Series D convertible preferred stock, $0.0001 par value per share, of CERo.
“Series E Certificate of Designations” refers to the Certificate of Designations of Rights and Preferences of the Series E Preferred Stock, as amended from time to time.
“Series E Preferred Stock” refers to the Series E convertible preferred stock, $0.0001 par value per share, of CERo.
“Sponsor” refers to Phoenix Biotech Sponsor, LLC, a Delaware limited liability company.
“Tertiary Earnout Shares” refer to the 500 shares of Common Stock issued to the holders of Legacy CERo common stock and Legacy CERo preferred stock in connection with the Business Combination, which became fully vested upon the achievement of certain regulatory milestone-based earnout targets.
“Third PIPE Financing” refers to the private placement pursuant to which we issued and sold, and the PIPE Investors purchased, shares of Series C Preferred Stock, on the terms and conditions set forth in the Third Securities Purchase Agreement.
“Third PIPE Registration Rights Agreement” refers to the Registration Rights Agreement, dated as of September 26, 2024, by and between CERo and certain PIPE Investors.
“Third Securities Purchase Agreement” refers to the Securities Purchase Agreement, dated as of September 25, 2024, by and among CERo and certain PIPE Investors, pursuant to which CERo agreed to issue and sell 2,853 shares of Series C Preferred Stock and Series C Warrants to purchase 4,088 shares of Common Stock.
“Warrant Common Shares” refer to the shares of Common Stock underlying the Common Warrants.
“Warrant Preferred Shares” refer to the shares of Preferred Stock underlying the Preferred Warrants
“Warrants” refer to the Rollover Warrants, the Private Placement Warrants, the Series A Warrants, the Series C Warrants, the December 2024 Common Warrants, the January 2025 Common Warrants, the Public Warrants, the February 2025 Common Warrants and the February 2025 Pre-Funded Warrants.
| ix |
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash, restricted cash, and cash equivalents | $ | $ | ||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Restricted cash | ||||||||
| Operating lease right-of-use assets, net | ||||||||
| Property and equipment, net | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Notes payable, net | $ | $ | ||||||
| Accounts payable | ||||||||
| Accrued liabilities | ||||||||
| Insurance payable | ||||||||
| Operating lease liability | ||||||||
| Preferred stock liabilities - Series E convertible preferred stock, $ | ||||||||
| Earnout liability | ||||||||
| Deemed dividend – common stock liability, | ||||||||
| Total current liabilities | ||||||||
| Long-term liabilities: | ||||||||
| Operating lease liability, net of current portion | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 14) | ||||||||
| Stockholders’ deficit: | ||||||||
| Preferred stock, par value $ | ||||||||
| Series C convertible preferred stock, $ | ||||||||
| Series D convertible preferred stock, $ | ||||||||
| Series E convertible preferred stock, $ | ||||||||
| Series A convertible preferred stock, $ | ||||||||
| Class A common stock; $ | ||||||||
| Additional paid-in capital | ||||||||
| Stock subscription receivable | ( | ) | ||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities and stockholders’ deficit | $ | $ | ||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 1 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| For the Three Months Ended September 30, |
For the Nine Months Ended September 30, |
|||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Total Operating Expenses | ||||||||||||||||
| Loss from Operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other Income (Expenses): | ||||||||||||||||
| (Loss) gain on foreign currency | ( | ) | ( | ) | ||||||||||||
| Gain (loss) on initial and revaluation of derivative liabilities | ( | ) | ||||||||||||||
| Gain from reevaluation of preferred stock liabilities | ||||||||||||||||
| Gain on debt extinguishment | ||||||||||||||||
| Change in fair value of earnout liability | ||||||||||||||||
| Stock-based inducement expense | ( | ) | ||||||||||||||
| Write off of deferred offering costs | ( | ) | ( | ) | ||||||||||||
| Interest income | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ||||||||||||
| Total Other Income (Expenses), net | ( | ) | ( | ) | ||||||||||||
| Net Income (Loss) | ( | ) | ( | ) | ( | ) | ||||||||||
| Deemed dividend on Series A, B, C, D and E Preferred Stock | ( | ) | ( | ) | ( | ) | ||||||||||
| Deemed dividend related to Series C Common Warrants | ( | ) | ||||||||||||||
| Net income (loss) attributable to common shareholders | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Net Income (Loss) per Common Share: | ||||||||||||||||
| Basic | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Diluted | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Weighted Average Common Shares Outstanding: | ||||||||||||||||
| Basic | ||||||||||||||||
| Diluted | ||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 2 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(Unaudited)
| Convertible Preferred Stock | Class A | Additional | Stock | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series A | Series B | Series C | Series D | Series E | Common Stock | Paid-in | Subscriptions | Accumulated | Stockholders’ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Receivable | Deficit | Deficit | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2025 | $ | $ | $ | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Sale of Common Stock under Keystone ELOC | - | - | - | - | - | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Common Stock on conversion of Series D Preferred Stock | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2026 | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sale of Common Stock under Keystone ELOC | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Common Stock on conversion of Series D Preferred Stock | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Common Stock on conversion of Series E Preferred Stock | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reclassification of fair value of preferred stock to preferred stock liabilities | - | - | - | - | ( | ) | - | ( | ) | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2026 | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Common Stock on conversion of Series D Preferred Stock | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Common Stock on conversion of Series E Preferred Stock | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reclassification of fair value of preferred stock from preferred stock liabilities - Series D | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reclassification of fair value of preferred stock liability to paid-in capital upon conversion | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||
| 3 |
| Convertible Preferred Stock | Class A | Additional | Stock | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series A | Series B | Series C | Series D | Series E | Common Stock | Paid-in | Subscriptions | Accumulated | Stockholders’ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Receivable | Deficit | Deficit | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Series A Preferred Stock upon exercise of Series A Preferred Warrants | - | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sale of common stock | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sale of pre-funded warrants, net of issuance costs of $ | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Exercise of pre-funded warrants | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of shares of Common Stock under Keystone ELOC | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Collection of stock subscriptions receivable related to prior Keystone ELOC purchases | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Common Stock upon conversion of Series A Preferred Stock | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Common Stock upon conversion of Series B Preferred Stock | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Redemption of Series C Preferred Stock | ( | ) | ( | ) | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based inducement expense related to conversion of Series A Preferred Stock | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2025 | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Exercise of pre-funded warrants | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of shares of Common Stock under Keystone ELOC, net of issuance costs of $ | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Common Stock upon conversion of Series B Preferred Stock | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Common Stock upon conversion of Series C Preferred Stock | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series D Preferred Stock for cash and equity securities, net of issuance costs of $ | - | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based inducement expense related to conversion of Series C Preferred Stock | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2025 | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of shares of Common Stock under Keystone ELOC, net of issuance costs of $ | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Common Stock upon conversion of Series C Preferred Stock | - | - | ( | ) | ( | ) | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of series D Preferred Stocks for cash, net of issuance costs of $ | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of shares of Common Stock upon conversion of Series D Preferred Stock | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Write off of subscription receivable | - | - | - | - | - | - | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 4 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| For the Nine Months Ended September 30, |
||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation expense | ||||||||
| Stock-based compensation | ||||||||
| Amortization of right-of-use operating lease asset | ||||||||
| Inducement expense | ||||||||
| Write off of deferred offering costs | ||||||||
| Amortization of debt discount | ||||||||
| Foreign currency transaction (loss) gain included in other income (expenses) | ( | ) | ||||||
| Loss on initial and revaluation of derivative liabilities | ||||||||
| Gain on revaluation of preferred stock liabilities | ( | ) | ||||||
| Gain on debt extinguishment | ( | ) | ||||||
| Gain on revaluation of earnout liability | ( | ) | ||||||
| Change in assets and liabilities: | ||||||||
| Prepaid expenses and other current assets | ( | ) | ||||||
| Accounts payable | ||||||||
| Accrued liabilities | ( | ) | ||||||
| Insurance payable | ( | ) | ||||||
| Operating lease liability | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Proceeds from sale of equity securities | ||||||||
| Net cash provided by investing activities | ||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from exercise of Series A Preferred warrants | ||||||||
| Proceeds from convertible notes payable, net | ||||||||
| Proceeds from notes payable | ||||||||
| Proceeds from share purchases under ELOC, net of issuance costs | ||||||||
| Proceeds received from sale of Series D Preferred Stock, net of issuance costs | ||||||||
| Proceeds received from sale of common stock and warrants | ||||||||
| Proceeds received from sale of pre-funded warrants, net of issuance costs | ||||||||
| Payment of deferred offering costs | ( | ) | ||||||
| Proceeds from exercise of pre-funded warrants | ||||||||
| Cash redemption of Series C Preferred Stock | ( | ) | ||||||
| Net cash provided by financing activities | ||||||||
| Net decrease in cash, restricted cash and cash equivalents | ( | ) | ( | ) | ||||
| Cash, restricted cash and cash equivalents at beginning of period | ||||||||
| Cash, restricted cash and cash equivalents at end of period | $ | $ | ||||||
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||||||||
The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the same such amounts shown in the consolidated statements of cash flows:
| Cash and cash equivalents | $ | $ | ||||||
| Restricted cash (short-term) | ||||||||
| Restricted cash (long-term) | ||||||||
| Cash, restricted cash and cash equivalents per consolidated statements of cash flows | $ | $ | ||||||
| Cash paid for: | ||||||||
| Interest | $ | $ | ||||||
| Income taxes | $ | $ | ||||||
| NON-CASH FINANCING ACTIVITIES: | ||||||||
| Conversion of Series A, Series B, Series C, Series D and Series E preferred stock to common stock | $ | $ | ||||||
| Increase in debt discount and derivative liabilities | $ | $ | ||||||
| Reclassification of convertible notes payable and accrued interest to notes payable | $ | $ | ||||||
| Reclassification of accounts payable to notes payable | $ | $ | ||||||
| Increase in operating lease right-of-use asset and operating lease liability | $ | $ | ||||||
| Reclassification of deferred offering costs to additional paid-in capital | $ | $ | ||||||
| Reclassification of accrued expenses to accounts payable | $ | $ | ||||||
| Issuance of Series D Preferred Stock for investment in equity securities | $ | $ | ||||||
| Write off of subscription receivable deemed offering costs | $ | $ | ||||||
| Reclassification of Series D and Series E preferred stock fair value to preferred stock liabilities | $ | $ | ||||||
| Reclassification of Series D preferred stock fair value from preferred stock liabilities to equity | $ | $ | ||||||
| Reclassification of Series E preferred stock fair value from preferred stock liabilities to paid-in capital upon conversion | $ | $ |
See accompanying notes to the unaudited condensed consolidated financial statements.
| 5 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS
Nature of Operations – CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo”, or the “Company”), F/K/A Phoenix Biotech Acquisition Corp. (“PBAX”) was incorporated in Delaware on June 8, 2021. PBAX was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses (a “business combination”).
The Company is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. The Company is in early clinical development but has not yet begun product commercialization. The Company’s efforts will focus on continued product development, including clinical development, to support regulatory approval to commercialize and subsequent product commercialization.
In November 2024, the U.S. Food and Drug Administration (“FDA”) cleared the Company’s Investigational New Drug Application for Phase 1 clinical trial of its lead compound, CER-1236, in acute myelogenous leukemia (“AML”), and in May 2025 announced the first patient was dosed with CER-1236 in a Phase 1/1b trial of AML. In June 2025, the Company announced the completion of the initial evaluation of the first patient in its Phase 1/1b trial without any dose-limiting toxicity and dosed the second AML patient in July 2025. In September 2025, the Company announced that it had dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in AML.
We submitted a second Investigational New Drug (“IND”) application for the investigation of CER-T cell therapy in NSCLC and ovarian cancer, which was accepted by the FDA on March 27, 2025.
Stock Purchase Agreement - On October 6, 2026, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with SRX Global Inc., a Delaware corporation formerly known as SRX Health Solutions, Inc. (“SRX” or the “Buyer”). Subject to the terms and conditions of the Purchase Agreement, the Company, subject to various closing conditions, may sell to the Buyer all of the outstanding capital stock of CERo Therapeutics, Inc., its wholly owned operating subsidiary (the “Subsidiary”), which sale is referred to herein as the “Transaction.” Upon completion of the Transaction (the “Closing”), the Company will cease to own the Subsidiary (See Note 15). In connection with signing the Purchase Agreement, the maturity date of the Consolidated Senior Secured Promissory Note entered into on August 27, 2026 (see Note 6) was extended to the date that is five (5) business days following the earlier of the Closing Date or the valid termination of the Purchase Agreement pursuant to its terms.
Nasdaq Delisting - On October 29, 2025, the Company received the determination of the Nasdaq Hearings Panel (the “Panel”) to deny the Company’s request to continue the listing of its shares of common stock on Nasdaq and that the trading in the Company’s securities would be suspended at the open of trading on October 31, 2025. The Company submitted a request for review of the Panel’s decision by the Nasdaq Listing and Hearing Review Council and was denied the listing on Nasdaq. On October 31, 2025, the Company’s shares of common stock commenced trading on the OTC Pink Sheets and are now traded on the OTCQB market.
Risks and Uncertainties – The Company is subject to all of the risks inherent in an early-stage biotechnology company. These risks include, but are not limited to, limited management resources, intense competition, and dependence upon the availability of cash to sustain operations. The Company’s operating results may be materially affected by the foregoing factors.
The Company’s research also requires approvals from the FDA prior to beginning clinical trials and prior to product commercialization. There can be no assurance that the Company’s current ongoing research and future clinical development will result in the granting of these required approvals. If the Company is denied such approvals or such approvals are substantially delayed, they could have a material adverse effect upon the Company’s future financial results and cash flows.
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the SEC. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
These unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on April 15, 2026. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the full year ending December 31, 2026 or for any future interim period.
The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, CERo Therapeutics, Inc., which was incorporated under the laws of Delaware on September 23, 2016. All significant intercompany balances and transactions have been eliminated in consolidation.
Reverse stock splits – On January 8, 2025, the Company effected a reverse stock split of our shares of common stock at a ratio of
All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these consolidated financial statements have been adjusted, on a retroactive basis, to reflect the Reverse Stock Splits.
| 6 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
Going concern – The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its research and development (“R&D”) activities and meet its obligations on a timely basis. As of September 30, 2026, the Company reported $
Based on current business plans, the Company believes that the cash available as of September 30, 2026 will not fund its operations and capital requirements for one year after the date these unaudited condensed consolidated financial statements are issued. During the nine months ended September 30, 2026, we received aggregate net proceeds of $
Additional funds are necessary to maintain current operations and to continue R&D activities. However, there can be no assurance that sufficient funding will be available to allow the Company to successfully continue its R&D activities and planned regulatory filings with the FDA. If the Company is unable to obtain the necessary funds, significant reductions in spending and the delay or cancellation of planned activities may be necessary. These actions would have a material adverse effect on the Company’s business, results of operations, and prospects. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within
On October 6, 2026, the Company entered into a Stock Purchase Agreement providing for the sale of its wholly owned operating subsidiary (see Note 15). If the Transaction is completed, the Company will no longer own the operating business through which it conducts its research and development activities, and its remaining assets would consist principally of the consideration received. The Transaction remains subject to closing conditions and there can be no assurance it will be completed.
Use of estimates – The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Items subject to such estimates and assumptions include the fair value of derivative liabilities, the fair value of preferred stock liabilities, the fair value of stock-based compensation expense, the present value of right-of-use assets and lease liabilities, the valuation of earnout liability, the value of deemed dividends and inducement expense, and the valuation allowance associated with deferred tax assets. Actual results could differ from those estimates.
Cash, restricted cash, and cash equivalents – The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less to be cash equivalents. As of September 30, 2026 and December 31, 2025, cash and cash equivalents consist of cash deposited with banks, including a money market sweep account, and restricted cash of $
Investment in equity securities - The Company’s investment in equity securities consisted of Series D Preferred Stock of Stella Diagnostics, Inc. (“Stella”), which was held by the Company as of June 30, 2025 and sold during the three months ended September 30, 2025. There was no gain or loss on the sale. Investments in equity securities were initially measured at cost. Cost was based upon either the cost of the investment or the estimated market value of the investment at the time it was acquired, whichever can be more clearly determined. The Company elected the measurement alternative for equity securities without readily determinable fair values. Under this alternative, if the Company identified an observable price change in an orderly transaction for an identical or similar investment of the same issuer, the Company measured the equity security at fair value as of the date that the observable transaction occurred. Any adjustments resulting from observable price changes were recognized in earnings. The Company monitored these investments for changes in observable prices from orderly transactions and assesses them for impairment. If an equity security was deemed to be impaired, an impairment loss is recognized in earnings, measured as the difference between the investment’s cost and its fair value at the impairment assessment date.
Concentration of credit risk – Financial instruments that potentially subject the Company to credit risk consist primarily of cash, restricted cash, and cash equivalents. The Company’s cash, restricted cash, and cash equivalents are on deposit with two financial institutions that management believes are of sufficiently high credit quality. Deposits at any of the Company’s financial institutions may, at times, exceed federal insured limits. As of September 30, 2026, deposits in excess of federal insured limits amounted to approximately $
Investor concentrations – Generally, the Company receives substantially all of its funding from two investors. The loss of these investors would have a material adverse effect on the Company’s consolidated results of operations and financial condition. If the Company is unable to obtain the necessary funds from new investors, significant reductions in spending and the delay or cancellation of planned activities may be necessary. These actions would have a material adverse effect on the Company’s business, results of operations, and prospects.
Property and equipment – Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, generally
| 7 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
Impairment of long-lived assets – The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. Through September 30, 2026, the Company has not experienced any impairment losses on its long-lived assets.
Leases – The Company determines whether an arrangement is or contains a lease at inception. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The lease term includes options to extend or terminate the lease only when the Company is reasonably certain to exercise them.
The Company’s leases do not provide an implicit rate. The Company therefore uses its incremental borrowing rate, based on information available at the commencement date, to determine the present value of lease payments. The ROU asset also includes lease payments made at or before commencement and initial direct costs, and is reduced by lease incentives.
Lease cost for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments are expensed as incurred and are not included in the measurement of ROU assets and lease liabilities. Examples include the Company’s share of operating expenses and taxes above base-year amounts, and charges for excess services.
The Company has elected the practical expedient to account for lease and non-lease components together as a single lease component for its real estate leases. It has also elected not to recognize ROU assets and lease liabilities for leases with a term of 12 months or less.
Derivative financial instruments – The Company evaluates financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. Derivative instruments are initially recorded at fair value on the issuance date and re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. Derivative assets and liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Preferred stock liabilities – The Company accounts for its convertible preferred stock as either equity or as a liability based on an assessment of the instrument’s rights and preferences under ASC 480 and ASC 815.
Under ASC 815-40, Derivatives and Hedging — Contracts in Entity’s Own Equity, a contract may be classified in equity only if the Company has sufficient authorized and unissued shares of common stock available to settle it. In May 2026, the issuance of additional convertible promissory notes and the reduction of the conversion price of the Company’s outstanding preferred stock from $
When authorized shares are insufficient, the Company applies a sequencing policy based on the latest inception date, under which instruments with the most recent inception dates are reclassified first. The Company’s sequencing policy is applied to its convertible preferred stock and to the embedded conversion features of its convertible notes payable. Share-based payment awards issued under the 2024 Plan and accounted for under ASC 718 are excluded from the sequencing policy.
Applying this policy, the Company determined that its Series E Convertible Preferred Stock no longer qualified for equity classification on May 5, 2026, and that its Series D Convertible Preferred Stock no longer qualified for equity classification on June 30, 2026. On each date the Company reclassified the instrument from stockholders’ equity to preferred stock liabilities at its fair value, resulting in reclassifications of $
Preferred stock liabilities are measured at fair value at each reporting date and immediately before reclassification or conversion. Changes in fair value are recognized in the consolidated statements of operations. The Company estimates fair value using an as-if-converted approach. This approach multiplies the number of common shares issuable upon conversion by the quoted closing price of the Company’s common stock on the measurement date. The number of shares issuable is derived from the $
On August 27, 2026, the Company completed a secured financing with SRX. As part of the transaction, it issued SRX a non-convertible Consolidated Senior Secured Promissory Note (the “Consolidated Note”) with an aggregate principal amount of $
Following this transaction, the Company has no convertible debt outstanding. The Company reassessed the classification of its preferred stock under its sequencing policy. It determined that sufficient authorized shares are now available to settle the Series D Convertible Preferred Stock, but not the Series E Convertible Preferred Stock. Accordingly, on August 27, 2026, the Company remeasured the Series D Convertible Preferred Stock to its fair value of $7,322,990 and reclassified it from preferred stock liabilities to stockholders’ equity. Gains and losses recognized before the reclassification were not reversed. The Series E Convertible Preferred Stock remains classified as a preferred stock liability as of September 30, 2026. It will continue to be remeasured at fair value until the Company has sufficient authorized shares to settle it, or until it is converted or otherwise settled.
| 8 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
During the nine months ended September 30, 2026, preferred stock liabilities activity consisted of the following:
| Series D Preferred Stock | Series E Preferred Stock | Total | ||||||||||
| Preferred stock liabilities balance on December 31, 2025 | $ | $ | $ | |||||||||
| Reclassification of fair value of preferred stock from equity to preferred stock liabilities | ||||||||||||
| Gain on changes in fair value recognized in consolidated statement of operations | ( | ) | ( | ) | ( | ) | ||||||
| Reclassification of fair value of preferred stock from preferred stock liabilities to equity | ( | ) | ( | ) | ||||||||
| Reclassification of fair value of preferred stock liability to paid-in capital upon conversion | ( | ) | ( | ) | ||||||||
| Preferred stock liabilities balance on September 30, 2026 | $ | $ | $ | |||||||||
For the three and nine months ended September 30, 2026, the Company recognized gains on the change in fair value of preferred stock liabilities of $
Earnout liability - As a result of the Merger in February 2024, the Company recognized an initial earnout liability of approximately $
Fair value measurements – Certain of the Company’s liabilities are carried at fair value. Fair value is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In determining fair value, the assumptions that market participants would use in pricing an asset or liability (the inputs) are based on a tiered fair value hierarchy consisting of three levels, as follows:
| Level 1 – | Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. |
| Level 2 – | Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. |
| Level 3 – | Unobservable inputs for which there is little or no market data and which require the Company to develop its own assumptions about how market participants would price the asset or liability. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. |
Carrying amounts of certain of the Company’s financial instruments, including cash, restricted cash, and cash equivalents, prepaid expenses and other current assets, notes payable, accounts payable, and accrued liabilities approximate fair value due to their relatively short maturities.
On September 30, 2026 and December 31, 2025, the fair value of the Company’s preferred stock liabilities and earnout liability was classified as follows:
| September 30, 2026 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Preferred stock liabilities – Series E Preferred | $ | $ | $ | $ | ||||||||||||
| Earnout liability | $ | $ | $ | $ | ||||||||||||
| December 31, 2025 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Earnout liability | $ | $ | $ | $ | ||||||||||||
| 9 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
The change in the fair value measurement using significant inputs (Level 3) for the nine months ended September 30, 2026 and 2025 for the Company is presented below:
| Level 3 | ||||
| Derivative liabilities: | ||||
| Balance at December 31, 2025 | $ | |||
| Initial fair value of conversion features allocated to debt discount | ||||
| Initial fair value of conversion features allocated to initial derivative expense | ||||
| Gain on revaluation of derivative liabilities | ( | ) | ||
| Derecognized upon extinguishment of debt included in gain on debt extinguishment | ( | ) | ||
| Balance at September 30, 2026 | $ | |||
| Earnout liability: | ||||
| Balance at December 31, 2024 | $ | |||
| Revaluation of earnout liability | ||||
| Balance at September 30, 2025 | $ | |||
| Earnout liability: | ||||
| Balance at December 31, 2025 | $ | |||
| Revaluation of earnout liability | ( | ) | ||
| Balance at September 30, 2026 | $ | |||
Research and development – R&D costs consist primarily of salaries and benefits, including stock-based compensation, occupancy, materials and supplies, contracted research, consulting arrangements, and other expenses incurred in the pursuit of the Company’s R&D programs. R&D costs are expensed as incurred.
Stock-based compensation – The Company periodically issues common stock and stock options to officers, directors, and consultants for services rendered. Stock-based compensation accounting requires the recognition of stock-based compensation expense, using a grant date fair value-based method, for costs related to all share-based payments including stock options and restricted stock awards granted to employees and non-employees. Companies are required to estimate the fair value of all share-based payment awards on the date of grant using an option pricing model, and the Company uses a Black-Scholes option pricing model (“Black-Scholes”) to estimate option award fair value. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment:
| ● | The Common Stock expected dividend yield assumption of |
| ● | The risk-free interest rate assumption is based on the U.S. Department of Treasury instruments whose term was most consistent with the expected life of the Company’s stock options. |
| ● | The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as the Company does not have sufficient public trading history for the Company’s Common Stock. The Company will continue to analyze the historical stock price volatility and expected term assumption as more historical price data for the Company’s Common Stock becomes available. |
| ● | The expected lives of the Company’s stock options are estimated based on the type of award issued using approaches that do not rely on the historical data of the Company, as management has concluded there is insufficient data to provide a reasonable forward-looking estimate. The expected life of an incentive stock option is estimated using the simplified method described in Staff Accounting Bulletin Topic 14 – Share-Based Payment. All incentive and non-qualified stock options awarded by the Company have terms consistent with this approach, which is to calculate the weighted average midpoint between the vesting date of each vesting tranche and the termination date of the option. |
The fair value of restricted stock awards is based upon the estimated share price of the common stock on the date of grant.
Forfeitures are accounted for as they occur. All options and restricted stock awards granted since inception are expensed on a straight-line basis over the requisite service period, which is usually the vesting period, or as certain performance-based vesting terms become probable. The related amounts are recognized in the consolidated statements of operations.
Income taxes – The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
The Company follows tax accounting requirements for the recognition, measurement, presentation, and disclosure in the financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. No liability related to uncertain tax positions is recorded in the financial statements. It is the Company’s policy to include penalties and interest expense related to income taxes as a component of income tax expense, as necessary. The Company has not recorded any interest or penalties associated with income tax. Tax years subsequent to 2022 are subject to examination by federal and state authorities.
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted, which included among other provisions the restoration of immediate expensing of domestic research and experimental (“R&E”) expenditures under Section 174. Pursuant to the OBBBA’s transition rules, the Company elected to expense all unamortized domestic R&E costs previously capitalized between 2022 and 2024.
| 10 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
Loss per common share – The Company reports both basic and diluted loss per common share. Basic loss per share is calculated based on the weighted average number of shares of common stock outstanding and excludes the dilutive effect of convertible preferred stock, warrants for convertible preferred stock or common stock, stock options or any other type of convertible securities. Diluted loss per common share is calculated based on the weighted average number of shares of common stock outstanding and when the effect of stock options, warrants and other types of convertible securities is dilutive, they are included in the calculation. Dilutive securities are excluded from the diluted loss per common share calculation if their effect is anti-dilutive, such as in periods where the Company reports a net loss (See Note 3).
Segment reporting - Operating segments are defined as components of a business for which separate discrete financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and assess performance. The Company operates as a operating and reporting segment, reflecting our sole focus in developing next generation engineered T cell therapeutics for the treatment of cancer. Our Chief Executive Officer serves as the Chief Operating Decision Maker (CODM), responsible for assessing the Company’s performance and making resource allocation decisions.
Accounting standards not yet adopted – In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires entities to provide more detailed disaggregation of expenses in the income statement, focusing on the nature of the expenses rather than their function. The new disclosures will require entities to separately present expenses for significant line items, including but not limited to, depreciation, amortization, and employee compensation. Entities will also be required to provide a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, disclose the total amount of selling expenses and, in annual reporting periods, provide a definition of what constitutes selling expenses. This pronouncement is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing this ASU to determine the impact on its consolidated financial statements.
In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270), Narrow-Scope Improvements, to provide clarity about the current requirements, rather than evaluate whether to expand or reduce interim disclosure requirements. The amendments in ASU 2025-11 result in a comprehensive list of interim disclosures that are required by GAAP. The amendments in ASU 2025-11 also include a disclosure principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendments in ASU 2025-11 are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027 and early adoption is permitted. The amendments in ASU 2025-11 can be applied either prospectively or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the disclosure impact that ASU 2025-11 may have on its financial statement presentation and disclosures.
Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company’s consolidated financial statements.
NOTE 3 – NET LOSS PER SHARE OF COMMON STOCK
The accounting standards require the presentation of both basic and diluted loss per common share on the face of the statements of operations. The Company’s basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of shares of common stock outstanding for the period. If there are dilutive securities, diluted loss per common share is computed by including common stock equivalents which includes shares issuable upon the exercise of stock options into shares of common stock, exercise of preferred warrants into shares of preferred stock, and conversion of preferred stock into shares of common stock, net of any shares assumed to have been purchased with the proceeds, using the treasury stock method.
For the three months ended September 30, 2026, the Company reported net income attributable to common stockholders, and diluted earnings per share was computed by applying the if-converted method to the outstanding convertible preferred stock and the treasury stock method to the outstanding stock options and warrants, with each class tested separately and applied in order of dilutive effect. The outstanding stock options and warrants had exercise prices in excess of the average market price of the common stock and produced no incremental shares. Application of the if-converted method to the outstanding convertible preferred stock requires reversal of the $
For the nine months ended September 30, 2026 and for the three and nine months ended September 30, 2025, the Company reported a net loss attributable to common stockholders and all potentially dilutive securities were excluded because their effect would have been anti-dilutive.
| 11 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
The following table presents a reconciliation of basic and diluted net income per common share for the three months ended September 30, 2026:
| Three Months Ended September 30, | ||||
| 2026 | ||||
| Net income per common share - basic: | ||||
| Net income attributable to common shareholders | $ | |||
| Weighted average common shares outstanding – basic | ||||
| Net income per common share – basic | $ | |||
| Net income per common share - diluted: | ||||
| Net income attributable to common shareholders – basic | $ | |||
| Less: gain on the revaluation of preferred stock liabilities | ( | ) | ||
| Numerator for income per common share – diluted | $ | |||
| Weighted average common shares outstanding – basic | ||||
| Add: dilutive shares related to: | ||||
| Convertible preferred stock | ||||
| Weighted average common shares outstanding – diluted | ||||
| Net income per common share – diluted | $ | |||
The following table summarizes the number of shares of Common Stock issuable upon conversion or exercise, as applicable, of preferred stock, stock options, and warrants that were not included in the calculation of diluted net income (loss) per share because such shares are anti-dilutive:
| For the three months ended September 30, | For the nine months ended September 30, | For the three and nine months ended September 30, | ||||||||||
| 2026 | 2026 | 2025 | ||||||||||
| Conversion of convertible preferred stock issued and outstanding | ||||||||||||
| Exercise of warrants for common stock | ||||||||||||
| Exercise of outstanding stock options | ||||||||||||
NOTE 4 – PROPERTY AND EQUIPMENT
Property and equipment, net, consisted of the following as of September 30, 2026 and December 31, 2025:
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Laboratory equipment | $ | $ | ||||||
| Computers | ||||||||
| Furniture | ||||||||
| Total cost | ||||||||
| Less: accumulated depreciation | ( | ) | ( | ) | ||||
| Property and equipment, net | $ | $ | ||||||
For the three months ended September 30, 2026 and 2025, depreciation expense was $
| 12 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
NOTE 5 – CONVERTIBLE NOTES PAYABLE
Convertible Notes Issued
During the nine months ended September 30, 2026, the Company issued convertible promissory notes (collectively, the “Convertible Notes”) to Keystone Capital Partners, LLC (“Keystone”) and SRX as follows:
| Note | Original Holder | Issue Date | Purchase Price | Principal | Maturity | ||||||||
| February 2026 Note | $ | $ | |||||||||||
| March 2026 Note | |||||||||||||
| April 2026 Note | |||||||||||||
| Second April Note | |||||||||||||
| May 2026 Note | |||||||||||||
| June 2026 advance | |||||||||||||
| July 2026 advance | |||||||||||||
| August 2026 advance | |||||||||||||
| Total | $ | $ | |||||||||||
Each Convertible Note was issued at a purchase price equal to
On June 23, July 14 and August 11, 2026, the Company and SRX amended and restated the May 2026 Note to increase the maximum loan amount to $
At any time, each holder could convert all or part of its outstanding principal and accrued but unpaid interest into common stock. The conversion price was the lesser of (i) $
Embedded Conversion Feature Derivative Liabilities
The conversion price of each Convertible Note varied with the market price of the Company’s common stock, so the embedded conversion feature is not indexed to the Company’s own stock under ASC 815-40-15. In addition, from May 2026 the Company had insufficient authorized shares to settle it (see Note 2). The Company concluded that the conversion feature was not clearly and closely related to the debt host, that the Convertible Notes were not measured at fair value through earnings, and that the feature would meet the definition of a derivative on a standalone basis. The Company further concluded that the feature did not qualify for the scope exception in ASC 815-10-15-74(a). The Company therefore bifurcated it and accounted for it as a derivative liability under ASC 815-15, Derivatives and Hedging – Embedded Derivatives.
At issuance, the aggregate fair value of the conversion feature derivatives was $
The derivative liabilities were remeasured to fair value at each reporting date and on August 27, 2026, with changes recognized in earnings. Fair value was estimated using a binomial valuation model, a Level 3 measurement, with the following assumptions:
| Nine months ended September 30, 2026 | ||||
| Expected dividend rate | ||||
| Expected term (years) | ||||
| Volatility | % | |||
| Risk-free interest rate | % | |||
| 13 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
Activity in the derivative liabilities for the nine months ended September 30, 2026 was as follows:
| Amount | ||||
| Balance, December 31, 2025 | $ | |||
| Initial fair value of conversion features allocated to debt discount | ||||
| Initial fair value of conversion features allocated to initial derivative expense | ||||
| Gain on revaluation of derivative liabilities | ( | ) | ||
| Derecognized upon extinguishment of debt included in gain on debt extinguishment | ( | ) | ||
| Balance, September 30, 2026 | $ | |||
For the three and nine months ended September 30, 2026, the Company recognized a net gain (loss) on derivative liabilities of $
Extinguishment of Convertible Notes
On August 27, 2026, the Company completed a secured financing with SRX and issued the non-convertible Consolidated Senior Secured Promissory Note (the “Consolidated Note”) described in Note 6. Before the transaction, Keystone sold its Convertible Notes to SRX. Because this was a transfer between creditors, it had no accounting effect for the Company.
The Consolidated Note replaced all outstanding Convertible Notes (the “Previous Notes”). Its principal amount of $
The Company first evaluated the exchange under ASC 470-60, Troubled Debt Restructurings by Debtors. It concluded that the exchange was not a troubled debt restructuring because the creditor granted no concession: the Consolidated Note’s principal equals the principal and accrued interest of the Previous Notes, and the effective borrowing rate did not decrease. The Company then evaluated the exchange under ASC 470-50. Because the exchange eliminated a substantive conversion option, the terms of the Consolidated Note are substantially different under ASC 470-50-40-10. The exchange was therefore accounted for as an extinguishment of the Previous Notes.
Immediately before the extinguishment, the Company remeasured the embedded conversion feature derivatives to their fair value of $
| Amount | ||||
| Principal of Previous Notes | $ | |||
| Less: unamortized debt discount | ( | ) | ||
| Accrued interest | ||||
| Fair value of embedded conversion feature derivatives | ||||
| Net carrying amount of extinguished debt | ||||
| Less: fair value of Consolidated Note (reacquisition price) | ( | ) | ||
| Gain on extinguishment of debt | $ | |||
The gain is included in “Gain on extinguishment of debt” in other income (expense) in the unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2026. Following the extinguishment, the Company had no convertible debt outstanding. As a result, it reassessed the classification of its convertible preferred stock (see Note 2, “Preferred Stock Liabilities”).
Interest Expense
For the three months ended September 30, 2026 and 2025, amortization of debt discounts related to the Convertible Notes was $
As of September 30, 2026 and December 31, 2025, the Company had convertible notes or related derivative liabilities outstanding.
| 14 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
NOTE 6 – NOTES PAYABLE
SRX
On August 27, 2026, the Company completed a secured financing transaction with SRX. In connection with the transaction, the Company issued to SRX the Consolidated Note. Prior to the transaction, SRX was a lender to the Company under certain of the convertible promissory notes described in Note 5. The Consolidated Note consolidates the Previous Notes, including (i) obligations under Previous Notes held by SRX in an aggregate amount of $
The Consolidated Note provides for additional advances by SRX to the Company of up to $
From August 27, 2026 to September 30, 2026, the Company received advances under the Consolidated Note from SRX in the gross amount of $
The outstanding principal amount of the Consolidated Note bears interest at
Except in connection with the consummation of a change of control Transaction, the Company may not prepay any amounts outstanding under the Consolidated Note without SRX’s prior written consent.
As security for the Company’s obligations under the Consolidated Note, the Company entered into a Pledge and Security Agreement with SRX, dated as of August 27, 2026 (the “Pledge Agreement”). Under the Pledge Agreement, the Company pledged and granted SRX a continuing security interest in all of the Company’s right, title and interest in the issued and outstanding capital stock of its subsidiary, CERo Therapeutics, Inc., together with any additional shares or other equity interests in Cero Therapeutics, Inc. subsequently acquired by the Company and all distributions and proceeds relating to those interests. The security interest created by the Pledge Agreement is intended to be a first-priority security interest. Cero Therapeutics, Inc. also entered into an Asset Security Agreement with SRX, dated as of August 27, 2026 (the “Asset Security Agreement”), pursuant to which Cero Therapeutics, Inc., granted SRX a continuing security interest in substantially all of Cero Therapeutics, Inc.’s assets. The collateral includes, among other assets, intellectual property, patents, patent applications, studies, clinical trials, regulatory applications and other assets relating to the Company’s and Cero Therapeutics, Inc.’s CER-T cell therapy business, including CER-1236. In addition, pursuant to a Guaranty of Payment dated as of August 27, 2026 (the “Guaranty”), Cero Therapeutics, Inc. absolutely, unconditionally and irrevocably guaranteed the payment and performance of the Company’s obligations under the Consolidated Note and the other transaction documents, including principal, interest, fees, enforcement costs and other amounts payable thereunder. The Guaranty is a guaranty of payment and performance and not merely a guaranty of collection.
The Consolidated Note contains customary negative covenants that, subject to specified exceptions, restrict the Company and its subsidiaries from, among other things, incurring additional indebtedness or liens, repaying certain other indebtedness, paying cash dividends or distributions on the Company’s equity securities, amending organizational documents in a manner materially adverse to SRX and entering into certain affiliate transactions.
Events of Default under the Consolidated Note include, among other matters, payment defaults; breaches of covenants, representations or warranties; certain cross-defaults under other material agreements; bankruptcy and insolvency events; certain judgments, levies or attachments; the incurrence of unpermitted indebtedness or liens; failure to use proceeds in accordance with the Company’s budget; the occurrence of a Material Adverse Effect; and the invalidity or unenforceability of a transaction document. Following an Event of Default, SRX may declare all outstanding principal and other amounts owing under the Consolidated Note immediately due and payable and may exercise its remedies against the pledged shares and other collateral.
In connection with the issuance of the Consolidated Note, the Previous Notes, including their conversion and other terms, were superseded and replaced in their entirety by the Consolidated Note. The unpaid principal and accrued interest under the Previous Notes were consolidated into the original principal amount of the Consolidated Note rather than repaid at the time of the transaction.
| 15 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
Other
On September 30, 2026, in connection with the Settlement Agreement with Goodwin Procter LLP described in Note 14, the Company’s wholly owned subsidiary, CERo Therapeutics, Inc., issued a promissory note to Goodwin in the principal amount of $
Events of default under the Goodwin Note include, among others: failure to pay principal when due; breach of a material covenant not cured within ten days after notice; a material misrepresentation; assignment for the benefit of creditors or appointment of a receiver or trustee; a money judgment exceeding $
Because the Goodwin Note was issued in a troubled debt restructuring accounted for under ASC 470-60, the Company did not impute interest on the Goodwin Note. The Goodwin Note is carried at its principal amount of $
On September 30, 2026 and December 31, 2025, notes payable, net consisted of the following:
| September 30, 2026 | December 31, 2025 | |||||||
| Consolidated Note with SRX | $ | $ | ||||||
| Promissory note with Goodwin | ||||||||
| Less: unamortized debt discount | ( | ) | ||||||
| Notes payable, net | ||||||||
| Less: current portion of notes payable | ( | ) | ||||||
| Notes payable, net – long-term | $ | $ | ||||||
For the three and nine months ended September 30, 2026, amortization of debt discount related to notes payable amounted to $
NOTE 7 – ACCRUED LIABILITIES
Accrued liabilities consisted of the following as of September 30, 2026 and December 31, 2025:
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Employee payroll related liabilities | $ | $ | ||||||
| Accrued franchise taxes | ||||||||
| Penalty for late S-1 filing and effectiveness | ||||||||
| Accrued interest payable | ||||||||
| Security deposits payable | ||||||||
| Accrued consulting and professional services | ||||||||
| $ | $ | |||||||
| 16 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
NOTE 8 – LEASE
Through September 30, 2026, the Company held a
On September 1, 2026, the Company entered into a lease agreement (the “Lease”) with SMBC Baker, LLC for approximately
Monthly base rent is $
In addition to base rent, the Company pays its
The Lease includes an option to extend the term for one additional two-year period, from October 1, 2028 through September 30, 2030, at specified base rents of $
The Lease is classified as an operating lease. At commencement, the Company recognized an operating lease liability of $
As required by the Lease, the Company delivered a $
The Company recorded the following lease costs:
| For the three months ended September 30, | For the three months ended September 30, | For the nine months ended September 30, | For the nine months ended September 30, | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating leases: | ||||||||||||||||
| Operating lease cost | $ | $ | $ | $ | ||||||||||||
| Variable operating lease cost | ||||||||||||||||
| Sublease income received | ( | ) | ( | ) | ||||||||||||
| Total lease cost | $ | $ | $ | $ | ||||||||||||
| 17 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
The right-of-use asset, net for the operating lease was recorded in the consolidated balance sheets as follows:
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Right-of-use asset, net | $ | $ | ||||||
The operating lease liability for the operating lease was recorded in the consolidated balance sheets as follows:
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Operating lease liability, current | $ | $ | ||||||
| Operating lease liability, non-current | ||||||||
| Total operating lease liability | $ | $ | ||||||
| Weighted-average remaining lease term of operating leases (in years) | ||||||||
| Weighted-average discount rate for operating leases | % | % | ||||||
Maturity of the Company’s lease liability as of September 30, 2026 is as follows:
| 2026 (remainder of year) | $ | |||
| 2027 | ||||
| 2028 | ||||
| Total lease payments | ||||
| Less: imputed interest | ( | ) | ||
| Total lease liability | $ |
NOTE 9 – STOCKHOLDERS’ DEFICIT
Series A Convertible Preferred Stock
The Company designated
Each share of Series A Preferred Stock has a stated value of $
Dividend and Participation Rights: The holders of Series A Preferred Stock are entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends actually paid on shares of Common Stock, when and if actually paid. Series A Preferred Stockholders are entitled to participate pro rata in any purchase rights extended to holders of Common Stock on an as-converted basis.
Conversion: Each holder of Series A Preferred Stock may convert at any time, all, or any part, of the outstanding Series A Preferred Stock into shares of the Common Stock at the initial “Conversion Price” of $
Alternate Conversion: Following the occurrence and during the continuance of a Trigger Event (as defined below), each holder may alternatively elect to convert the Series A Preferred Stock at the “Alternate Conversion Price” equal to the lesser of the Conversion Price and the greater of $
| 18 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
Redemptions: Upon bankruptcy or liquidation, Series A Preferred Stock is redeemed at a
The holders of the Series A Preferred Stock have no voting rights.
In February 2024, the Company consummated a private placement (the “Series A PIPE Financing”) of
A portion of such Series A Preferred Stock was issued as consideration for the cancellation of outstanding indebtedness, including a promissory note of PBAX amounting to $
The Company accounts for preferred stock as either equity or debt-like securities based on an assessment of the Preferred Stock rights and preferences and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging. Prior to May 5, 2026, the Company concluded that Series A, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, and Series E Preferred Stock, which have no cash redemption features outside of the Company’s control, are treated as equity. The Company has also concluded that the Series A Common Warrants and Series C Common Warrants do not possess redemption features outside of the Company’s control and are treated as equity. In May 2026, as a result of the issuance of additional convertible promissory notes and the reduction of preferred stock conversion prices from $
During the three months ended March 31, 2025, the
During the nine months ended September 30, 2025,
Additionally, certain investors are owed an aggregate of
During the three and nine months ended September 30, 2026, Series D Preferred Stock and Series E Preferred Stock were converted by investors at a conversion price lower than the conversion price of the Series A Preferred Stock then in effect. The lower conversion price lowered the Series A Preferred Stock conversion price from $
As of September 30, 2026, there were
Series B Convertible Preferred Stock
The Company designated
| 19 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
The holders of the Series B Preferred Stock have no voting rights.
The Series B Preferred Stock ranks pari passu with the Series A Preferred Stock.
Due to delayed filing and declaration of effectiveness relative to the deadlines defined in the Registration Rights Agreement, through December 31, 2024, the Company accrued a registration rights penalty amounting to $
During the three months ended March 31, 2025,
As of September 30, 2026 and December 31, 2025, there were remaining shares of Series B Preferred Stock.
Series C Convertible Preferred Stock
The Company designated
Each share of Series C Preferred Stock has a stated value of $
Ranking: The Series C Preferred Stock are senior in rank with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company to the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, and Common Stock. The Company shall not, without the consent of the Required Holders, authorize or issue any shares of senior rank with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company, shares of pari passu rank with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company, or shares of junior ranking stock that have a maturity or redemption date prior to the first anniversary of the Series C Preferred Stock issuance date.
Dividend and Participation Rights: The holders of Series C Preferred Stock are entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends actually paid on shares of Common Stock, when and if actually paid. Series C Preferred Stockholders will be entitled to participate pro rata in any purchase rights extended to holders of Common Stock on an as-converted basis.
Conversion: Each holder of Series C Preferred Stock may convert at any time, all, or any part, of the outstanding Series C Preferred Stock into shares of the Common Stock at the initial “Conversion Price” of $
Alternate Conversion: Following the occurrence and during the continuance of a Trigger Event (as defined below), each holder may alternatively elect to convert the Series C Preferred Stock at the “Alternate Conversion Price” equal to the lesser of the then current Conversion Price and the greater of $
Redemptions: Upon bankruptcy or liquidation, Series C Preferred Stock will be redeemed at a
| 20 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
The holders of the Series C Preferred Stock have no voting rights.
In September 2024, the Company consummated a private placement (the “Series C PIPE Financing”) of
The Company accounts for preferred stock as either equity or debt-like securities based on an assessment of the Preferred Stock rights and preferences and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging. The Company has concluded that the Series C Preferred Stock, which has no cash redemption features outside of the Company’s control, is treated as equity. The Company has also concluded that the Series C Common Warrants do not possess redemption features outside of the Company’s control and are treated as equity.
On March 10, 2025, the Company paid certain investors $
During the three months ended June 30, 2025,
On July 18, 2025,
During the three and nine months ended September 30, 2026, Series D Preferred Stock and Series E Preferred Stock were converted by investors at a conversion price lower than the contractual conversion price of the Series C Preferred Stock then in effect. The triggering event lowered the Series C Preferred Stock conversion price from $
As of September 30, 2026 and December 31, 2025, there were
Series D Convertible Preferred Stock
On April 22, 2025, the Company designated
General. Each share of Series D Preferred Stock has a stated value of $
Ranking. The Series D Preferred Stock, with respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company, ranks senior to all capital stock of the Company (including the Series A Preferred Stock and the Series B Preferred Stock, except for the Series C Preferred Stock, which will rank pari passu) unless the Required Holders (as defined in the Series D Certificate of Designations) consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series D Preferred Stock.
Dividends. The holders of Series D Preferred Stock will be entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends actually paid on shares of the Company’s Common Stock, when and if actually paid.
Purchase Rights. If at any time the Company grants, issues or sells any options, convertible securities, or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the “Series D Purchase Rights”), then each holder of Series D Preferred Stock will be entitled to acquire, upon the terms applicable to such Series D Purchase Rights, the aggregate Series D Purchase Rights which such holder could have acquired if such holder had held the number of shares of Common Stock acquirable upon complete conversion of all the Series D Preferred Stock held by such holder immediately prior to the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Series D Purchase Rights at the Series D Alternate Conversion Price (as defined below); subject to certain limitations on beneficial ownership.
| 21 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
Conversion Rights
Conversion at Option of Holder. Each holder of Series D Preferred Stock may convert all, or any part, of the outstanding Series D Preferred Stock, at any time at such holder’s option, into shares of the Common Stock (which converted shares of Common Stock are referred to as “Series D Conversion Shares” herein) at the fixed “Series D Conversion Price” of $
Voluntary Adjustment Right. Subject to the rules and regulations of the Nasdaq, the Company has the right, at any time after the Stockholder Approval Date (as defined below), with the written consent of the Required Holders, to lower the fixed conversion price to any amount and for any period of time deemed appropriate by the board of directors of the Company.
Alternate Conversion Upon a Triggering Event. Following the occurrence and during the continuance of a Series D Triggering Event (as defined below), each holder may alternatively elect to convert the Series D Preferred Stock at the “Series D Alternate Conversion Price” equal to the lesser of:
| ● | The applicable Conversion Price, and |
| ● | the greater of: |
| ● | the floor price of $ |
| ● |
The Series D Certificate of Designations contains standard and customary triggering events (each, a “Series D Triggering Event”), including but not limited to: (i) the suspension from trading or the failure to list the Common Stock within certain time periods; (ii) failure to declare or pay any dividend when due; (iii) the failure to timely file or make effective a registration statement on Form S-1 or Form S-3 pursuant to the Registration Rights Agreement (as defined below), (iv) the Company’s failure to cure a conversion failure or notice of the Company’s intention not to comply with a request for conversion of any Series D Preferred Stock, and (v) bankruptcy or insolvency of the Company.
Other Adjustments. In connection with the April 2025 Private Placement (see below), the Company agreed to seek stockholder approval at a special meeting of stockholders, of the issuance of Conversion Shares at a conversion price below the Conversion Price (the date of such approval, the “Series D Stockholder Approval Date”). If the Company did not obtain such stockholder approval prior to May 31, 2025, then the Company would have been required to (i) file a preliminary Proxy Statement seeking such stockholder consent with the SEC no later than May 31, 2025, (ii) use reasonable best efforts to file the definitive Proxy Statement no later than June 30, 2025 and (iii) use reasonable best efforts to hold the Stockholder Meeting no later than July 31, 2025. Such stockholder approval was obtained on May 29, 2025. If, on or after the Series D Stockholder Approval Date, the Company issues any shares of Common Stock for a consideration per share (the “Series D New Issuance Price”) less than a price equal to the Series D Conversion Price in effect immediately prior to such issuance, the Conversion Price shall be reduced to the Series D New Issuance Price.
If 30 days or 60 days following the occurrence of the later of (x) the Series D Stockholder Approval Date and (y) the earlier of (a) the effective date of the registration statement to be filed pursuant to the Registration Rights Agreement and (b) the date that the Series D Preferred Stock is eligible to be resold without restriction under Rule 144 of the Securities Act, the Series D Conversion Price then in effect is greater than the greater of $
On August 13, 2025, the Company and the Investors of Series D Preferred Stock entered into an Amendment and Limited Waiver Agreement (the “Waiver Agreement”), whereby the Investors (i) amended the Registration Rights Agreement to extend certain deadlines therein and (ii) waived certain provisions of the Series D COD. Pursuant to the Waiver Agreement, the Company and the Series D Preferred Holders acknowledged that it was inefficient and impracticable to file the Registration Statement prior to the consummation of additional closings. Accordingly, the filing deadline with respect to the initial Registration Statement was extended to August 15, 2025; The Registration Statement on Form S-3 was filed on August 11, 2025. Additionally, the “Effectiveness Deadline” with respect to the initial Registration Statement required to be filed, shall be the earlier of the (A) October 15, 2025 (or, if such Registration Statement is subject to a full review by the SEC, November 30, 2025 and (B) fifth Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that such Registration Statement will not be reviewed or will not be subject to further review and (ii) with respect to any additional Registration Statements that may be required to be filed by the Company pursuant to this Waiver Agreement, the earlier of the (A) ninetieth (90th) calendar day following the date on which the Company was required to file such additional Registration Statement and (B) fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that such Registration Statement will not be reviewed or will not be subject to further review. The Registration Statement on Form S-3 was declared effective on August 15, 2025. Furthermore, during the second quarter of 2025, the Company issued shares of Common Stock (the “Existing Series C Conversion Shares”) upon conversion of shares of Series C Preferred Stock at conversion prices below the Conversion Price of the Series D Preferred Stock (the “Existing Series C Conversions”), which each of the Company and Holder acknowledges was mutually beneficial. Pursuant to the Waiver Agreement, the Series D Preferred Holders waived Section 8(a) of the Series D COD, in part, solely with respect to the Existing Series C Conversions, such that the Prior Series C Conversion Shares were deemed “Excluded Securities” under Section 8(a) (the “Antidilution Waiver”).
Bankruptcy Triggering Event Redemption Right. Upon any bankruptcy Series D Triggering Event, the Company shall immediately redeem in cash all amounts due under the Series D Preferred Stock at a
| 22 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
Change of Control Exchange. Upon a change of control of the Company, each holder may require the Company to exchange the holder’s shares of Series D Preferred Stock for consideration equal to the Change of Control Election Price (as defined in the Series D Certificate of Designations), to be satisfied at the Company’s election in either (x) cash or (y) rights convertible into such securities or other assets to which such holder would have been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by such holder upon consummation of such corporate event.
Company Optional Redemption. At any time the Company shall have the right to redeem in cash all, but not less than all, the shares of Series D Preferred Stock then outstanding at a
Fundamental Transactions. The Series D Certificate of Designations prohibits the Company from entering specified fundamental transactions (including, without limitation, mergers, business combinations and similar transactions) unless the Company (or the Company’s successor) assumes in writing all of the Company’s obligations under the Certificate of Designations and the other Transaction Documents (as defined in the Series D Certificate of Designations).
Voting Rights. The holders of the Series D Preferred Stock shall have no voting power and no right to vote on any matter at any time, either as a separate series or class or together with any other series or class of share of capital stock, and shall not be entitled to call a meeting of such holders for any purpose nor shall they be entitled to participate in any meeting of the holders of Common Stock, except as provided in the Series D Certificate of Designations (or as otherwise required by applicable law).
Covenants. The Series D Certificate of Designations contains a variety of obligations on the Company’s part not to engage in specified activities. In particular, the Company will not, and will cause the Company’s subsidiaries to not, redeem, repurchase or declare any dividend or distribution on any of the Company’s capital stock (other than as required under the Series D Certificate of Designations) and will not incur any indebtedness other than ordinary course trade payables or, subject to certain exceptions, incur any liens. In addition, the Company will not issue any preferred stock or issue any other securities that would cause a breach or default under the Series D Certificate of Designations.
Reservation Requirements. So long as any Series D Preferred Stock remains outstanding, the Company shall at all times reserve at least 250% of the number of shares of Common Stock as shall from time to time be necessary to effect the conversion of all Series D Preferred Stock then outstanding.
On April 21, 2025, the Company entered into a Securities Purchase Agreement (the “Fourth Securities Purchase Agreement”) with certain accredited investors. Pursuant to the Fourth Securities Purchase Agreement, up to
On April 22, 2025, pursuant to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a private placement (the “Fourth PIPE Financing”),
On June 5, 2025, the Company sold an additional
On June 25, 2025, we entered into an amendment (the “Amendment”) to the Fourth Securities Purchase Agreement pursuant to which the Company added certain new institutional investors to the schedule of buyers in the Fourth Securities Purchase Agreement, to issue and sell to such investors, in one or more closings shares of the Company’s Series D Preferred Stock. Also, on June 25, 2025, we sold an additional
On July 18, 2025, the Company sold an additional
On September 15, 2025, the 30th day following the effective date of the registration statement to be filed pursuant to the Registration Rights Agreement, the conversion price of Series D Preferred Stock was lowered to from $
| 23 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
During the three months ended September 30, 2025, 200 shares of Series D Preferred Stock were converted into
During the three and nine months ended September 30, 2026, Series D Preferred Stock and Series E Preferred Stock were converted by investors at a conversion price lower than the contractual conversion price of the Series D Preferred Stock then in effect. The triggering event lowered the Series D Preferred Stock conversion price from $
During the three months ended March 31, 2026,
As of September 30, 2026, there were
As a result of the issuance of additional convertible promissory notes and the reduction of preferred stock conversion prices from $
Series E Convertible Preferred Stock
On October 14, 2025, the Company filed the Certificate of Designations of Rights and Preferences of the Series E Preferred Stock (the “Series E Certificate of Designations”) establishing and designating
General. Each share of Series E Preferred Stock has a stated value of $
Ranking. The Series E Preferred Stock, with respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company, ranks senior to all capital stock of the Company (except the Series A convertible preferred stock which will rank senior to the Series E Preferred Stock and except for the Series C convertible preferred stock and Series D convertible preferred stock, which will rank pari passu to the Series E Preferred Stock) unless the Required Holders (as defined in the Fifth Securities Purchase Agreement) consent to the creation of other capital stock of the Company that is senior or equal in rank to the Series E Preferred Stock.
Dividends. The holders of Series E Preferred Stock will be entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends actually paid on shares of the Common Stock, when and if actually paid.
Purchase Rights. If at any time the Company grants, issues or sells any options, convertible securities, or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the “Series E Purchase Rights”), then each holder of Series E Preferred Stock will be entitled to acquire, upon the terms applicable to such Series E Purchase Rights, the aggregate Series E Purchase Rights which such holder could have acquired if such holder had held the number of shares of Common Stock acquirable upon complete conversion of all the Series E Preferred Stock (without taking into account any limitations or restrictions on the convertibility of the Series E Preferred Stock and assuming for such purpose that all the Series E Preferred Stock held by such holder were converted at the Series E Alternate Conversion Price (as defined below) in effect as of the applicable record date); subject to certain limitations on beneficial ownership.
| 24 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
Conversion Rights
Conversion at Option of Holder. Each holder of Series E Preferred Stock may convert all, or any part, of the outstanding Series E Preferred Stock, at any time at such holder’s option, into shares of the Common Stock (which converted shares of Common Stock are referred to as “Conversion Shares” herein) at the initial fixed “Series E Conversion Price” of $
Voluntary Adjustment Right. Subject to the rules and regulations of Nasdaq, the Company has the right, at any time after the Stockholder Approval Date (as defined below), with the written consent of the Required Holders, to lower the fixed Series E Conversion Price to any amount and for any period of time deemed appropriate by the Board of Directors.
Alternate Optional Conversion. After the Stockholder Approval Date, at any time, at the option of the holder, the holder may convert the Series E Preferred Stock at the “Series E Alternate Optional Conversion Price” equal to the lesser of:
| ● | The applicable Series E Conversion Price, and |
| ● | the greater of: |
| ● | the floor price of $ |
| ● |
Alternate Conversion Upon a Triggering Event. Following the occurrence and during the continuance of a Triggering Event (as defined below), each holder may alternatively elect to convert the Series E Preferred Stock at the “Series E Alternate Triggering Event Conversion Price” (and together with the Series E Alternate Optional Conversion Price, each an “Series E Alternate Conversion Price”) equal to the lesser of:
| ● | The applicable Series E Conversion Price, and |
| ● | the greater of: |
| ● | the floor price of $ |
| ● |
The Series E Certificate of Designations contains standard and customary triggering events (each, a “Series E Triggering Event”), including but not limited to: (i) the suspension from trading or the failure to list the Common Stock within certain time periods; (ii) failure to declare or pay any dividend when due; (iii) the failure to timely file or make effective a registration statement on Form S-1 or Form S-3 pursuant to the Registration Rights Agreement (as defined below), (iv) the Company’s failure to cure a conversion failure or notice of the Company’s intention not to comply with a request for conversion of any Series E Preferred Stock, and (v) bankruptcy or insolvency of the Company.
Other Adjustments. In connection with the Private Placement, the Company has agreed to seek stockholder approval at a special meeting of stockholders, of the issuance of Conversion Shares at a conversion price below the Series E Conversion Price (the date of such approval, the “Series E Stockholder Approval Date”). If the Company has not otherwise obtained such stockholder approval prior to October 31, 2025, which did not occur, then the Company shall (i) file a preliminary Proxy Statement seeking such stockholder consent with the SEC no later than October 31, 2025, (ii) use reasonable best efforts to file the definitive Proxy Statement no later than November 30, 2025 and (iii) use reasonable best efforts to hold the Stockholder Meeting no later than December 31, 2025 (the “Stockholder Meeting Deadline”). The Company filed its preliminary Proxy Statement on November 17, 2025, filed its definitive Proxy Statement on November 28, 2025, and held its annual meeting on December 19, 2025. If, on or after the Series E Stockholder Approval Date, the Company issues any shares of Common Stock for a consideration per share (the “New Issuance Price”) less than a price equal to the Series E Conversion Price in effect immediately prior to such issuance (each, a “Dilutive Issuance”), the Series E Conversion Price shall be reduced to the New Issuance Price; provided that, if any Dilutive Issuances or other events that would have resulted in an adjustment to the Series E Conversion Price prior to the Series E Stockholder Approval Date, the Series E Conversion Price shall automatically adjust to such New Issuance Price on the Series E Stockholder Approval Date. Accordingly, on December 19, 2025, the conversion price of the Series E Preferred Stock was reduced to $
Bankruptcy Triggering Event Redemption Right. Upon any bankruptcy Series E Triggering Event, the Company shall immediately redeem in cash all amounts due under the Series E Preferred Stock at a
Change of Control Exchange. Upon a change of control of the Company, each holder may require the Company to exchange the holder’s shares of Series E Preferred Stock for consideration equal to the Change of Control Election Price (as defined in the Series E Certificate of Designations), to be satisfied at the Company’s election in either (x) cash or (y) rights convertible into such securities or other assets to which such holder would have been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by such holder upon consummation of such corporate event.
Company Optional Redemption. At any time the Company shall have the right to redeem in cash all, but not less than all, the shares of Series E Preferred Stock then outstanding at a
| 25 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
Fundamental Transactions. The Series E Certificate of Designations prohibits the Company from entering specified fundamental transactions (including, without limitation, mergers, business combinations and similar transactions) unless the Company (or the Company’s successor) assumes in writing all of the Company’s obligations under the Series E Certificate of Designations and the other Transaction Documents (as defined in the Series E Certificate of Designations).
Voting Rights. The holders of the Series E Preferred Stock shall have no voting power and no right to vote on any matter at any time, either as a separate series or class or together with any other series or class of share of capital stock, and shall not be entitled to call a meeting of such holders for any purpose nor shall they be entitled to participate in any meeting of the holders of Common Stock, except as provided in the Series E Certificate of Designations (or as otherwise required by applicable law).
Covenants. The Series E Certificate of Designations contains a variety of obligations on the Company’s part not to engage in specified activities. In particular, the Company will not, and will cause the Company’s subsidiaries to not, redeem, repurchase or declare any dividend or distribution on any of the Company’s capital stock (other than as required under the Series E Certificate of Designations) and will not incur any indebtedness other than ordinary course trade payables or, subject to certain exceptions, incur any liens. In addition, the Company will not issue any preferred stock or issue any other securities that would cause a breach or default under the Series E Certificate of Designations.
Reservation Requirements. So long as any Series E Preferred Stock remains outstanding, the Company shall at all times reserve at least 250% of the number of shares of Common Stock as shall from time to time be necessary to effect the conversion of all Series E Preferred Stock then outstanding.
On October 14, 2025, the Company entered into the Fifth Securities Purchase Agreement with certain accredited investors named therein, pursuant to which the Company agreed to issue and sell up to
On October 16, 2025, pursuant to the Fifth Securities Purchase Agreement, the Company issued and sold, and certain investors purchased
The Fifth Securities Purchase Agreement includes the consent of the holders of the Company’s outstanding Series C and Series D Preferred Stock to the issuance of the Series E Preferred Stock pari passu therewith, in consideration for the reduction of the conversion price for the Company’s outstanding Series C and Series D convertible preferred stock to $
On December 19, 2025, the date of the Special Meeting of the Company, the stockholders of the Company approved, subject to certain conditions, the issuance of shares of Common Stock in accordance with Nasdaq Listing Rule 5635, upon the conversion of the Company’s Series E Preferred Stock. Pursuant to the Series E Certificate of Designations, the Series E Conversion Price shall automatically adjust to such New Issuance Price on the Series E Stockholder Approval Date. Since October 14, 2025, the Company converted Series C Preferred Stock at a lower price than the Series E conversion price then in effect of $
During the three and nine months ended September 30, 2026, Series D Preferred Stock and Series E Preferred Stock were converted by investors at a conversion price lower than the contractual conversion price of the Series E Preferred Stock then in effect. The triggering event lowered the Series E Preferred Stock conversion price from $
Registration Rights Agreement
On October 14, 2025, the Company entered into the Fifth Registration Rights Agreement, pursuant to which the Company filed a registration statement with the SEC, to register for resale the Common Stock issuable upon the conversion of the Series E Preferred Stock.
During the three months ended June 30, 2026, approximately
| 26 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
As of September 30, 2026, there were
On May 5, 2026, as a result of the issuance of convertible promissory notes and the reduction of preferred stock conversion prices from $
Purchase of Common Stock by Keystone Capital Partners under the Equity Line of Credit (“ELOC”)
On February 14, 2024, in conjunction with, and as a condition to the closing of the Series A PIPE Financing, the Company entered into a common stock purchase agreement with Keystone Capital Partners, LLC (“Keystone”), pursuant to which we may sell and issue, and Keystone is obligated to purchase, up to
During the three months ended March 31, 2025, the Company sold
During the three months ended June 30, 2025, the Company sold
During the three months ended September 30, 2025, the Company sold
During the three months ended March 31, 2026, the Company sold
During the three months ended June 30, 2026, the Company sold
Sale of Pre-funded Warrants and Common Stock
On February 5, 2025, the Company announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i)
| 27 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
The Warrants have an exercise price of $
In connection with the Offering, on February 5, 2025, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Alliance Global Partners (“A.G.P.”), as the exclusive placement agent in connection with the Offering (the “Placement Agent”). Pursuant to a side letter between the Placement Agent and JonesTrading Institutional Services LLC (“Jones”), dated February 3, 2025, Jones agreed to be a financial advisor for the Offering. In connection with the services provided by Jones, the Placement Agent and Jones agreed that the Placement Agent will receive an aggregate fee equal to
The Company’s directors and executive officers agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any shares of common stock or other securities convertible into or exercisable or exchangeable for common stock for a period of 90 days following the closing date of the Offering, which terms may be waived in the sole discretion of and without notice by the Placement Agent, subject to certain exceptions. In addition, the Company has agreed to not enter into variable rate financings for a period of 180 days following the closing date, subject to certain exceptions, or enter into any equity financings for a period of 60 days following the closing date, subject to certain exceptions.
In connection with the Offering, the Conversion Price of the Series A Preferred Stock and Series C Preferred Stock reset to $
NOTE 10 – WARRANTS
A summary of outstanding warrants as of September 30, 2026 is as follows:
| Number of Warrants | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (in years) | ||||||||||
| Public and Private Placement Warrants | $ | |||||||||||
| February 2024 Series A Common Warrants | ||||||||||||
| September 2024 Series C Common Warrants | ||||||||||||
| December 2024 Common Warrants | ||||||||||||
| January 2025 Common Warrants | ||||||||||||
| February 2025 Pre-funded Warrants | ||||||||||||
| February 2025 Common Warrants | ||||||||||||
| Outstanding as of September 30, 2026 | $ | |||||||||||
On September 30, 2026, the intrinsic value of the warrants amounted to $
NOTE 11 – STOCK-BASED COMPENSATION
On March 25, 2024, stockholders approved the 2024 Employee Stock Purchase Plan (the “2024 ESPP”), with initial reserves of
On March 25, 2024, stockholders approved the 2024 Equity Incentive Plan (the “2024 Plan”), with initial reserves of
| 28 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
On January 7, 2026, the Company’s Board of Directors granted an aggregate of
On March 4, 2026, the Company’s Board of Directors granted an aggregate of
The Company’s stock option activity for the nine months ended September 30, 2026 was as follows:
| Weighted | ||||||||||||
| Weighted | Average | |||||||||||
| Average | Remaining | |||||||||||
| Outstanding | Exercise | Contractual | ||||||||||
| Stock | Price Per | Life | ||||||||||
| Options | Share | (in Years) | ||||||||||
| Balance, December 31, 2025 | $ | |||||||||||
| Options granted | ||||||||||||
| Balance, September 30, 2026 | $ | |||||||||||
| Options exercisable as of September 30, 2026 | $ | |||||||||||
The Company estimated the fair value of the stock options during the nine months ended September 30, 2026 and 2025 using Black-Scholes with the following assumptions.
| Nine Months Ended September 30, | Nine Months Ended September 30, | |||||||
| 2026 | 2025 | |||||||
| Risk-free interest rate | % | % | ||||||
| Expected life (in years) | ||||||||
| Expected dividend yield | % | % | ||||||
| Expected volatility | % | % | ||||||
For the three months ended September 30, 2026, the Company recorded stock-based compensation expense of $
For the three months ended September 30, 2025, the Company recorded stock-based compensation expense of $
As of September 30, 2026, the Company had approximately $
NOTE 12 – 401(K) RETIREMENT SAVINGS PLAN
The Company sponsors a 401(k) defined contribution plan covering eligible employees who elect to participate. The Company is allowed to make discretionary profit sharing and 401(k) matching contributions as defined in the plan and as approved by the Board of Directors. The Company’s accrued contributions for the nine months ended September 30, 2026 were $
| 29 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
NOTE 13 – RELATED-PARTY TRANSACTIONS
On February 5, 2025, the Company announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i)
The following table summarizes the pre-funded warrants and February 2025 Common Warrants sold to our related party:
| Purchasers | Pre-Funded Warrants Purchased | Total Purchase Price | February 2025 Common Warrants Issued | |||||||||
| Atwood-Edminster Trust dtd 4-2-2000 and GVN, LLC (1) | $ | |||||||||||
| (1) |
On April 22, 2025, pursuant to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a private placement (the “Fourth PIPE Financing”),
During the three months ended September 30, 2026 and 2025, the Company incurred consulting fees of $
NOTE 14 – COMMITMENTS AND CONTINGENCIES
Legal matters
From time to time, the Company may be involved in litigation or receive claims arising out of our operations in the normal course of business. We are not currently a party to any other legal proceeding nor are we aware of claims that we believe would, if decided adversely, have a material adverse effect on the Company’s business, financial condition, or operating results.
Settlement Agreement with Former Legal Counsel
On September 30, 2026 (the “Effective Date”), the Company and its wholly owned subsidiary, CERo Therapeutics, Inc. (the “Operating Subsidiary”), entered into a Settlement and Release Agreement (the “Settlement Agreement”) with Goodwin Procter LLP (“Goodwin”), the Company’s former legal counsel, to resolve unpaid fees for legal services totaling approximately $
Under the Settlement Agreement, the Company agreed to deliver the following consideration in full satisfaction of the Outstanding Debt: (i) a cash payment of $
Goodwin agreed to forbear from collection actions on the Outstanding Debt while the Company complies with the Settlement Agreement, until the earlier of March 31, 2027 or the commencement of a liquidation, wind-up, or dissolution of the Operating Subsidiary or the special purpose vehicle. Goodwin’s release of the Company from claims relating to the Outstanding Debt becomes effective only upon receipt of the cash payment, issuance and repayment in full of the Note by March 31, 2027, and completion of the Equity Grant. If the Company fails to perform, the forbearance terminates and Goodwin may pursue all available remedies, including collection of the Outstanding Debt.
As of September 30, 2026, the remaining liability of $
| 30 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
The Company has not recognized a liability for the Equity Grant. The special purpose vehicle has not been formed and the Transaction has not closed, and accordingly the fair value of the Equity Grant was not reasonably estimable at September 30, 2026. The Company will measure and recognize the Equity Grant, and reassess the restructuring, in the period in which the Transaction closes and the vehicle is formed to date.
See Note 8 for leases.
NOTE 15 – SUBSEQUENT EVENTS
Stock Purchase Agreement
On October 6, 2026, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with SRX. Subject to the terms and conditions of the Purchase Agreement, the Company will sell to the Buyer all of the outstanding capital stock of CERo Therapeutics, Inc., its wholly owned operating subsidiary (the “Subsidiary”), which sale is referred to herein as the “Transaction.” Upon completion of the Transaction (the “Closing”), the Company will cease to own the Subsidiary. In connection with signing the Stock Purchase Agreement, the maturity date of the Consolidated Note entered into on August 27, 2026 was extended to the date that is five (5) business days following the earlier of the Closing Date or the valid termination of the Stock Purchase Agreement pursuant to its terms.
At Closing, the Company will receive (i) shares of SRX common stock determined by dividing $
The Purchase Agreement provides a 30-day go-shop period beginning on the signing date and ending thirty (30) days from the signing date (the “Go-Shop Period”). During this period, the Company and its representatives may actively solicit, initiate, facilitate, and encourage alternative acquisition proposals and provide nonpublic information under acceptable confidentiality agreements. The Company has retained Joseph Gunnar & Co., LLC to conduct the go-shop process. The Company must notify SRX within 24 hours after receipt of an acquisition proposal during the Go-Shop Period, identify the bidder and summarize the material terms, and keep SRX reasonably informed of material developments.
If the Company receives a Superior Proposal before the Go-Shop Period expires, the Purchase Agreement provides up to 45 additional days after the go-shop end date to negotiate that proposal and execute a definitive agreement. A “Superior Proposal” must, among other requirements, be a bona fide written proposal that the Company’s board determines in good faith, after consultation with its financial advisor and outside counsel, is more favorable to the Company than the Transaction, taking into account any revisions proposed by SRX. The proposal must not be subject to third-party financing and must require consummation no later than March 15, 2027. A qualifying alternative acquisition proposal must also contemplate full repayment of Company obligations under the Consolidated Note and related security documents, release of the related liens and payment of the applicable termination fee to SRX.
After the Go-Shop Period, the Purchase Agreement restricts further solicitation, information sharing, and negotiations, subject to negotiation of any Superior Proposal received during the Go-Shop Period, provisions and a fiduciary exception for qualifying unsolicited written proposals. Before terminating the Purchase Agreement to enter into an agreement for a Superior Proposal, the Company must comply with the applicable procedures, including at least three business days’ prior written notice to SRX and, if requested, good-faith negotiations regarding revisions offered by SRX. A material amendment to the competing proposal requires a new two-business-day notice period. The Company’s board must determine that the competing proposal remains superior after considering SRX’s proposed revisions, and the Company must pay the applicable termination fee in connection with termination.
The go-shop process expired with no Superior Proposals.
The Stock Purchase Agreement was entered into on October 6, 2026, after the balance sheet date. The Go-Shop Period provided for in the Purchase Agreement expired on November 5, 2026. No acquisition proposals were received during the Go-Shop Period or through the date of this filing. The Company evaluated the criteria in ASC 360-10-45-9 and concluded that the Subsidiary did not meet all the criteria to be classified as held for sale as of September 30, 2026. Accordingly, the assets and liabilities of the Subsidiary have not been reclassified in the accompanying unaudited condensed consolidated balance sheet. If the Transaction is completed, the Company expects the Subsidiary to be presented as a discontinued operation in accordance with ASC 205-20 in the period in which the held-for-sale criteria are met.
The Purchase Agreement may be terminated in specified circumstances, including by mutual agreement, upon a final legal prohibition, for specified uncured breaches, or if Closing has not occurred by the applicable outside date. The Company may also terminate to enter into an agreement for a Superior Proposal in compliance with the go-shop procedures, and the Buyer may terminate for a breach of the go-shop provisions or an adverse change in the Company’s board recommendation.
The Company is required to pay a $
| 31 |
CERO THERAPEUTICS HOLDINGS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
The Purchase Agreement also provides for reimbursement of up to $
The Closing of the Transaction is conditioned upon SRX’s acquisition of the shares of the Company’s Series C, Series D and Series E preferred stock.
The Closing of the Transaction is also conditioned upon the holders of the Company’s Series A preferred stock holding the requisite percentage or amount of such preferred stock providing the applicable waivers or consents and/or converting their Series A preferred stock into the Company’s common stock, in each case as specified in the transaction documents.
In evaluating arrangements to satisfy the Series A preferred stock closing condition, discussions have occurred regarding potential minority equity participation in a post-closing acquisition entity; any such arrangements, if finalized, remain subject to definitive documentation, mutual agreement with the applicable preferred holders, and review by the Special Committee.
Completion remains subject to the satisfaction or permitted waiver of the applicable closing conditions, including specified consents, the accuracy of representations and warranties, material compliance with covenants, the absence of specified material adverse effects, the preferred stock arrangements described above, and delivery of the required transaction documents. The Company’s conditions include SRX’s funding of the required advances and delivery of the registration rights agreement providing for registration of the resale of the SRX shares issued to the Company or their subsequent distribution to the Company’s stockholders, and requiring SRX to use commercially reasonable efforts to obtain and maintain the effectiveness of the applicable registration statements, subject to the terms of that agreement. The Buyer’s obligations are not subject to a financing condition.
The Purchase Agreement contemplates Closing on the first business day following the end of the Go-Shop Period on which the closing conditions are satisfied or waived, unless the parties agree otherwise in writing, subject to the applicable Superior Proposal provisions.
The Company’s board, acting on the unanimous recommendation of a special committee of independent and disinterested directors, approved the Purchase Agreement and the Transaction. The Purchase Agreement contemplates the sale of pledged collateral under Section 272 of the Delaware General Corporation Law (“DGCL”). Pursuant to Section 272 of the DGCL, the Company’s board determined that the Shares constitute collateral pledged to SRX pursuant to the Pledge Agreement, that the sale represents an alternative sale of pledged collateral in lieu of foreclosure resulting in the elimination and reduction of the secured debt, and that the fair market value of the Shares does not exceed the total amount of secured liabilities and obligations being eliminated, discharged, or assumed by Buyer. Accordingly, no vote or consent of the holders of the Company’s common stock is required under Delaware law to authorize or consummate the Transaction, subject to the satisfaction of the preferred stock closing conditions described above.
The Purchase Agreement contains representations, warranties and covenants, including restrictions on the Subsidiary’s conduct before Closing. It contemplates employment agreements with certain key employees, 180-day lock-up agreements for specified recipients of consideration shares, and registration rights relating to the SRX shares. Pursuant to the Purchase Agreement, the Company may obtain, at its cost and expense, a prepaid “tail” directors’ and officers’ liability insurance policy covering current and former directors and officers of the Company and the Subsidiary, funded in part from funds previously set aside by the Company for such purpose. In addition, Buyer has unconditionally guaranteed all indemnification, advancement, and exculpation obligations of the Subsidiary, and effective upon the Closing, Buyer, on behalf of itself, its affiliates, and the acquired Subsidiary, has agreed to deliver a comprehensive mutual release extinguishing all pre-closing claims and liabilities against the Company and its current and former officers, directors, employees, and advisors, with such individuals designated as express third-party beneficiaries entitled to enforce such protections directly.
Advances on the Consolidated Note
During the period from October 1, 2026 to November 13, 2026, the Company received advances under the Consolidated Note from SRX in the gross amount of $
Conversion of Series D Preferred Shares
During the period from October 1, 2026 to November 13, 2026,
| 32 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations provides information that CERo Therapeutics Holdings, Inc. (“the Company”) management believes is relevant to an assessment and understanding of its results of operations and financial condition. The discussion should be read together with (i) the Company’s unaudited condensed consolidated financial statements and related notes that are presented above and (ii) the Company’s audited consolidated financial statements and related notes and management’s discussion and analysis of financial condition and results of operations included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2026. This Management’s Discussion and Analysis of Financial Condition and Results of Operations may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Actual results may differ materially from those anticipated in these forward-looking statements resulting from various factors. Please see “Cautionary Note Regarding Forward Looking Statements” and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC.
Overview
CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo”, or the “Company”), F/K/A Phoenix Biotech Acquisition Corp. (“PBAX”) was incorporated in Delaware on June 8, 2021. PBAX was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses (a “business combination”).
The Company is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. The Company is in early clinical development but has not yet begun product commercialization. The Company’s efforts will focus on continued product development, including clinical development, to support regulatory approval to commercialize and subsequent product commercialization.
Going concern
The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its research and development (“R&D”) activities and meet its obligations on a timely basis. As of September 30, 2026, the Company reported $650,681 of cash, restricted cash, and cash equivalents, a working capital deficit of approximately $19.3 million, and an accumulated deficit and stockholders’ deficit of approximately $93.7 million and $18.8 million, respectively. Additionally, during the nine months ended September 30, 2026, the Company used approximately $8.1 million of net cash in operating activities, had a net loss of approximately $2.9 million and has no revenues. During the nine months ended September 30, 2026, we received aggregate net proceeds of $7.1 million, consisting of $700,491 from the sale of common stock in connection with ELOC fundings, $4,485,200 from the issuance of Convertible Notes and $1,925,600 of net advances under the Consolidated Note. Additional funds are necessary to maintain current operations and to continue R&D activities. However, there can be no assurance that sufficient funding will be available to allow the Company to successfully continue its R&D activities and planned regulatory filings with the FDA. If the Company is unable to obtain the necessary funds, significant reductions in spending and the delay or cancellation of planned activities may be necessary. These actions would have a material adverse effect on the Company’s business, results of operations, and prospects. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these unaudited condensed consolidated financial statements are issued. These unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
During the nine months ended September 30, 2026, we received net proceeds of $700,491 from the sale of our common stock from ELOC fundings. Furthermore, during the nine months ended September 30, 2026, we issued and sold convertible notes having an aggregate principal face value of $5,606,500, and the Company received net proceeds of $4,485,200, and we received advances pursuant to Consolidated Note in the amount of $1,925,600.
Additional funds are necessary to maintain current operations and to continue R&D activities. However, there can be no assurance that sufficient funding will be available to allow the Company to successfully continue its R&D activities and planned regulatory filings with the FDA. If the Company is unable to obtain the necessary funds, significant reductions in spending and the delay or cancellation of planned activities may be necessary. These actions would have a material adverse effect on the Company’s business, results of operations, and prospects. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date the unaudited consolidated financial statements are issued. These unaudited consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
On October 6, 2026, the Company entered into a Stock Purchase Agreement providing for the sale of its wholly owned operating subsidiary (see Note 15). If the Transaction is completed, the Company will no longer own the operating business through which it conducts its research and development activities, and its remaining assets would consist principally of the consideration received. The Transaction remains subject to closing conditions and there can be no assurance it will be completed.
Recent Developments
Consolidated Note Payable
On August 27, 2026, we completed a secured financing transaction with SRX. In connection with the transaction, we issued to SRX the Consolidated Note. Prior to the transaction, SRX was a lender to the Company under certain of the convertible promissory notes described in Note 5. The Consolidated Note consolidates the Previous Notes, including (i) obligations under Previous Notes held by SRX in an aggregate amount of $2,794,000 and (ii) obligations under Previous Notes originally held by Keystone in an aggregate amount of $2,872,109, consisting of $2,812,500 of principal and $59,609 of accrued and unpaid interest. Before the transaction, Keystone sold its Convertible Notes to SRX. Because this was a transfer between creditors, it had no accounting effect for the Company. Accordingly, the principal amount of the Consolidated Note represented by previously outstanding debt was $5,666,109, and such amounts were lent to the Company on an unsecured basis.
| 33 |
The Consolidated Note provides for additional advances by SRX to the Company of up to $6,000,000 in the aggregate, inclusive of the initial advance described below, resulting in a maximum aggregate Consolidated Note amount of $11,666,109. Provided that no Event of Default has occurred and is continuing as determined under the terms of the Consolidated Note, the Consolidated Note provides for additional funding advances to the Company on the first day of each calendar month following the original issue date and before the maturity date in the amounts set forth in the Consolidated Note, reflecting Company’s budget attached to the Consolidated Note. SRX may, in its sole and absolute discretion, make additional advances reasonably requested by the Company, subject to the $6,000,000 aggregate advance limit.
From August 27, 2026 to September 30, 2026, the Company received advances under the Consolidated Note from SRX in the gross amount of $1,975,600, and received net proceeds of $1,925,600, which is net of $50,000 reimbursement of SRX’s legal expenses, which amount was withheld from the initial advance and treated as a debt discount to be amortized into interest expense over the term. During the period from October 1, 2026 to November 13, 2026, the Company received advances under the Consolidated Note from SRX in the gross amount of $1,424,673 and received net proceeds of $1,424,673. The Company intends to use the proceeds of the advances to pay outstanding trade payables and for working capital purposes of the Company. Interest that is not paid when due may be recorded as an additional advance under the Note.
The outstanding principal amount of the Note bears interest at 10% per annum, calculated on the basis of a 30-day month and a 360-day year. During the existence of an Event of Default, the outstanding obligations bear interest at the lesser of (i) 24.99% per annum and (ii) the maximum rate permitted by applicable law. If the Event of Default is cured, the interest rate returns to 10% per annum. The unpaid principal amount, accrued and unpaid interest and all other amounts payable under the Consolidated Note were due and payable on October 15, 2026, unless earlier accelerated or otherwise paid in accordance with the Note. Provided that no Event of Default has occurred and is continuing, SRX may extend the maturity date for up to four consecutive 30-day periods by providing the Company with at least one business day’s prior written notice. In connection with signing the Stock Purchase Agreement, the maturity date of the Consolidated Note entered into on August 27, 2026 was extended to the date that is five (5) business days following the earlier of the Closing Date or the valid termination
Stock Purchase Agreement
On October 6, 2026, we entered into a Stock Purchase Agreement (the “Purchase Agreement”) with SRX Global Inc., a Delaware corporation formerly known as SRX Health Solutions, Inc. (“SRX” or the “Buyer”). Subject to the terms and conditions of the Purchase Agreement, we will sell to the Buyer all of the outstanding capital stock of CERo Therapeutics, Inc., our wholly owned operating subsidiary (the “Subsidiary”), which sale is referred to herein as the “Transaction.” Upon completion of the Transaction (the “Closing”), we will cease to own the Subsidiary (See Note 15). In connection with signing the Purchase Agreement, the maturity date of the Consolidated Senior Secured Promissory Note entered into on August 27, 2026 (see Note 6) was extended to the date that is five (5) business days following the earlier of the Closing Date or the valid termination of the Purchase Agreement pursuant to its terms.
FDA Designation
In July 2025, CER-1236 received an FDA Orphan Drug Designation for the treatment of acute myeloid leukemia. In September 2025, the FDA granted Fast Track Designation to our lead investigational compound, CER-1236 for acute myeloid leukemia, which is in addition to the existing Orphan Drug Designation for the same compound. The FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious or life-threatening conditions with unmet medical need. The designation provides us with the opportunity for increased FDA interactions, potential eligibility for priority review, and the ability to submit data on a rolling basis.
Other
The Company’s shares of Common Stock commenced trading on OTCQB as of December 2, 2025. On January 29, 2026, after considering the written record in this matter, the Nasdaq Listing and Hearing Review Council issued its decision affirming the Panel’s decision to delist the Company’s securities from Nasdaq.
Results of Operations
Revenue
The Company has not recognized any revenue from any sources, including from product sales, and the Company does not expect to generate any revenue from the sale of products in the foreseeable future. If the development efforts for the Company’s product candidates, each of which is a specific product and indication combination, are successful and result in regulatory approval, or if the Company executes license agreements with third parties, the Company may generate revenue from R&D services, from the achievement of development milestones or from milestones and royalties related to product sales. However, there can be no assurance as to when any revenues will be generated, if at all.
Operating Expenses
Research and Development Expenses
R&D expenses consist of discovery activities, manufacturing development and production, preclinical and clinical development, and regulatory filing for product candidates. R&D expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in R&D are capitalized until the goods or services are received. Costs incurred in obtaining technology licenses through asset acquisitions, if incurred, will be charged to R&D expense if the licensed technology has not reached technological feasibility and has no alternative future use. R&D expenses include or could include:
| ● | employee-related expenses, including salaries, bonuses, benefits, stock-based compensation and other related costs for those employees involved in R&D efforts; |
| ● | external R&D expenses incurred under agreements with preclinical research organizations, clinical research organizations, investigative sites, centralized clinical laboratories, and consultants to conduct preclinical and clinical studies; |
| ● | costs related to manufacturing material for preclinical studies and clinical trials, including fees paid to contract development and manufacturing organizations; |
| ● | product-liability insurance for clinical development product(s); |
| ● | laboratory supplies and research materials; |
| 34 |
| ● | software and systems related to R&D activities; |
| ● | costs related to regulatory filing and compliance; and |
| ● | facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, maintenance of facilities, and equipment. |
Product candidates in later stages of development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. The Company plans to substantially increase its R&D expenses for the foreseeable future as it continues the development of its product candidates through clinical development. The Company cannot determine with certainty the timing of initiation, the duration or the costs of current or future preclinical studies and clinical trials required for regulatory approval due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. The Company anticipates that it will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and ongoing assessments as to each product candidate’s commercial potential. The Company will need to, and plans to, raise substantial additional capital in the future. Future R&D expenses may vary significantly between periods and from current expectations based on factors such as:
| ● | expenses incurred to conduct preclinical studies required to advance product candidates into clinical trials; |
| ● | per patient clinical trial costs based on a number of factors, including number of patient clinical visits, clinical laboratory testing, and potential medical imaging; |
| ● | the number of clinical trials required for approval, the number of patients who enroll in each clinical trial, and the number and geographic locations of sites included in the clinical trials; |
| ● | the length of time required to screen and enroll eligible patients, screen-failure rate, or the discontinuation rates of enrolled patients; |
| ● | potential additional safety monitoring requested by regulatory agencies; |
| ● | the cost of insurance, including product liability insurance, in connection with clinical trials; and |
| ● | suspension or termination of clinical development activities by regulators or institutional review boards for various reasons, including regulatory noncompliance or a finding that the participants are being exposed to unacceptable health risks. |
General and Administrative Expenses
General and administrative expenses consist principally of salaries and related costs for personnel in executive and administrative functions, including stock-based compensation, travel expenses and recruiting expenses. Other general and administrative expenses include professional fees for legal, accounting and tax-related services, consulting fees, insurance costs, and investor relations fees.
The Company anticipates that its general and administrative expenses will increase in the future as the Company increases headcount and contracted services for operational support for expanded operations and infrastructure. The Company also anticipates that general and administrative expenses will increase as a result of expenses for accounting, audit, legal and consulting services, as well as costs associated with maintaining compliance with SEC requirements, director and officer liability insurance, investor and public relations activities and other expenses associated with operating as a public company.
Other Income (Expenses), Net
Other expenses, net consists predominantly of interest income from interest bearing bank accounts, interest expense, and gains or losses on the initial valuation and revaluation of earnout, derivative liabilities and preferred stock liabilities, which represents the initial fair value and change in fair value of conversion options related to our convertible notes payable between periods.
| 35 |
Results of Operations for the Three Months ended September 30, 2026 and 2025
Results of operations for the three months ended September 30, 2026 and 2025 are summarized as follows:
| For the Three Months Ended September 30, | Percentage | |||||||||||||||
| 2026 | 2025 | Change | Change | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 1,973,857 | $ | 2,386,244 | $ | (412,387 | ) | 17.3 | % | |||||||
| General and administrative | 1,219,068 | 1,976,335 | (757,267 | ) | 38.3 | % | ||||||||||
| Total operating expenses | 3,192,925 | 4,362,579 | (1,169,654 | ) | 26.8 | % | ||||||||||
| Loss from operations | (3,192,925 | ) | (4,362,579 | ) | 1,169,654 | 26.8 | % | |||||||||
| Other income (expenses): | ||||||||||||||||
| Loss on foreign currency | (2,039 | ) | 248 | (2,287 | ) | 922.2 | % | |||||||||
| Gain (loss) on initial and revaluation of derivative liabilities | 604,371 | - | 604,371 | - | ||||||||||||
| Gain on reevaluation of preferred stock liabilities | 3,724,886 | - | 3,724,886 | - | ||||||||||||
| Gain on debt extinguishment | 3,801,413 | 3,801,413 | - | |||||||||||||
| Write off of deferred offering costs | - | (500,000 | ) | 500,000 | 100.0 | % | ||||||||||
| Interest income | 1,075 | 5,936 | (4,861 | ) | 81.9 | % | ||||||||||
| Interest expense | (917,669 | ) | - | (917,669 | ) | - | ||||||||||
| Total other income (expenses), net | 7,212,037 | (493,816 | ) | 7,705,853 | 1,560.5 | % | ||||||||||
| Net income (loss) | 4,019,112 | (4,856,395 | ) | 8,875,507 | 182.8 | % | ||||||||||
| Deemed dividend on Series A, B, C, D and E Preferred Stock | - | (6,649,828 | ) | 6,649,828 | 100.0 | % | ||||||||||
| Net income (loss) attributable to common stockholders | $ | 4,019,112 | $ | (11,506,223 | ) | $ | 15,525,335 | 134.9 | % | |||||||
Research and Development Expenses
Research and development expenses were $1,974,000 for the three months ended September 30, 2026, compared to $2,386,000 for the three months ended September 30, 2025, reflecting a decrease of $412,000. The decrease was related to decreased R&D activity in the 2026 period as compared to the 2025 period. During the 2025 period, the Company prepared and filed the IND for CER-1236, prepared for the clinical trials initiation, and began the clinical trial. The decrease in research and development expenses primarily reflected (i) a decrease in clinical expenses of $92,000, (ii) a decrease in scientific consulting expenses of $241,000, and (iii) a decrease in drug manufacturing costs of $171,000, offset by an increase in other costs of $92,000.
The Company anticipates that its R&D expenses may increase in the future if the Company increases headcount, compensation expense, and contracted services for preclinical and clinical development of its product candidates, as well as for manufacturing of clinical product to be used in clinical development.
General and Administrative Expenses
General and administrative expenses were $1,219,000 for the three months ended September 30, 2026, compared to $1,976,000 for the three months ended September 30, 2025, reflecting a decrease of $757,000. The decrease in the three months ended September 30, 2026 over the three months ended September 30, 2025 was partially due to a decrease in stock-based stock options expense of approximately $201,000, a decrease in other compensation and benefits of $42,000 and a decrease in professional fees of $344,000 and a decrease in other general and administrative expenses of approximately $170,000.
Other Income (Expenses), Net
Other income (expenses), net was $7,212,000 for the three months ended September 30, 2026, compared to other expenses, net of $(494,000) for the three months ended September 30, 2025, reflecting a positive change of $7,706,000. The positive change during the three months ended September 30, 2026 as compared to the three months ended September 30, 2025 was primarily due to the recording of a gain on reevaluation of preferred stock liabilities of $3,725,000, the absence of the $500,000 write off of deferred offering costs recorded in the 2025 period, the recording of a gain on initial and revaluation of derivative liabilities of $604,000, and the recording of a gain on debt extinguishment of $3,801,000, offset by the recording of interest expense of $918,000 related to the issuance of convertible notes and notes payable during the 2026 period, a decrease in interest income of $5,000, and an increase in loss on foreign currency of $2,000.
Net loss and net loss attributable to common stockholders
For the three months ended September 30, 2026 and 2025, net income (loss) amounted to $4,019,000 and $(4,856,000), respectively, a positive change of $8,875,000, or 182.8%. During the three months ended September 30, 2026 and 2025, in connection with our Series A, Series B, Series C, Series D and Series E preferred stock conversions, we recorded deemed dividends of $0 and $6,650,000, respectively. Accordingly, for the three months ended September 30, 2026 and 2025, net income (loss) attributable to common stockholders amounted to $4,019,000, or $0.06 per common share and $11,506,000, or $9.10 per common share, respectively.
| 36 |
Results of Operations for the Nine Months ended September 30, 2026 and 2025
Results of operations for the nine months ended September 30, 2026 and 2025 are summarized as follows:
| For the nine months Ended September 30, | Percentage | |||||||||||||||
| 2026 | 2025 | Change | Change | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 6,048,214 | $ | 8,048,034 | $ | (1,999,820 | ) | 24.8 | % | |||||||
| General and administrative | 5,836,905 | 5,988,867 | (151,962 | ) | 2.5 | % | ||||||||||
| Total operating expenses | 11,885,119 | 14,036,901 | (2,151,782 | ) | 15.3 | % | ||||||||||
| Loss from operations | (11,885,119 | ) | (14,036,901 | ) | 2,151,782 | 15.3 | % | |||||||||
| Other income (expenses): | ||||||||||||||||
| Gain on foreign currency | (1,918 | ) | 248 | (2,166 | ) | 873.4 | % | |||||||||
| Gain (loss) on initial and revaluation of derivative liabilities | (3,395,884 | ) | - | (3,395,884 | ) | - | ||||||||||
| Gain on reevaluation of preferred stock liabilities | 10,335,126 | - | 10,335,126 | - | ||||||||||||
| Gain on debt extinguishment | 3,801,413 | - | 3,801,413 | - | ||||||||||||
| Change in fair value of earnout liabilities | 19,500 | - | 19,500 | - | ||||||||||||
| Share-based inducement expenses | - | (863,550 | ) | 863,550 | 100.0 | % | ||||||||||
| Write off of deferred offering costs | - | (500,000 | ) | (500,000 | ) | 100.0 | % | |||||||||
| Interest income | 5,249 | 20,562 | (15,313 | ) | 74.5 | % | ||||||||||
| Interest expense | (1,773,999 | ) | - | (1,773,999 | ) | - | ||||||||||
| Total other income (expenses), net | 8,989,487 | (1,342,740 | ) | 10,332,227 | 769.5 | % | ||||||||||
| Net loss | (2,895,632 | ) | (15,379,641 | ) | 12,484,009 | 81.2 | % | |||||||||
| Deemed dividend on Series A, B, C, D and E Preferred Stock | (28,426,624 | ) | (31,614,346 | ) | 3,187,722 | 10.0 | % | |||||||||
| Deemed dividend related to Series C Common Warrants | - | (84,083 | ) | 84,083 | 100.0 | % | ||||||||||
| Net loss attributable to common stockholders | $ | (31,322,256 | ) | $ | (47,078,070 | ) | $ | 15,755,814 | 33.5 | % | ||||||
Research and Development Expenses
Research and development expenses were $6,048,000 for the nine months ended September 30, 2026, compared to $8,048,000 for the nine months ended September 30, 2025, reflecting a decrease of $2,000,000. The decrease was related to decreased R&D activity in the 2026 period as compared to the 2025 period. During the 2025 period, the Company prepared and filed the IND for CER-1236, prepared for the clinical trials initiation, and began the clinical trial. The decrease in research and development expenses reflected (i) a decrease in clinical expenses of $1,531,000, (ii) a decrease in scientific consulting expenses of $710,000, (iii) a decrease in lab and other expenses of $151,000, (iv) a decrease in other expenses of $169,000, and (v) a decrease in drug manufacturing costs of $71,000. These decreases were offset by and stock-based stock option expense of approximately $632,000.
The Company anticipates that its R&D expenses may increase in the future as the Company increases headcount, compensation expense, and contracted services for preclinical and clinical development of its product candidates, as well as for manufacturing of clinical product to be used in clinical development.
General and Administrative Expenses
General and administrative expenses were $5,837,000 for the nine months ended September 30, 2026, compared to $5,989,000 for the nine months ended September 30, 2025, reflecting a decrease of $152,000. The decrease in the nine months ended September 30, 2026 over the nine months ended September 30, 2025 was partially due to a decrease in professional fees of $996,000, a decrease in proxy and transfer agent fees of $634,000, and a decrease in other general and administrative expenses of approximately $74,000, offset by an increase in stock-based stock options expense of approximately $1,393,000 and an increase in insurance expense of $159,000.
Other Income (Expenses), Net
Other income (expenses), net was $8,989,000 for the nine months ended September 30, 2026, compared to other expenses, net of $(1,343,000) for the nine months ended September 30, 2025, a positive change of $10,332,000. The positive change during the nine months ended September 30, 2026 as compared to the nine months ended September 30, 2025 was primarily due to the recording of a gain on reevaluation of preferred stock liabilities of $10,335,000, a gain on debt extinguishment of $3,801,000, a reduction in stock-based inducement expense of $864,000, and a decrease in the write off of deferred offering costs of $500,000, offset by the recording of a loss on initial and revaluation of derivative liabilities of $3,396,000, and the recording of interest expense of $1,774,000 related to the issuance of convertible notes and notes payable during the 2026 period.
Net loss and net loss attributable to common stockholders
For the nine months ended September 30, 2026 and 2025, net loss amounted to $2,896,000 and $15,380,000, respectively, a decrease of $12,484,000, or 81.2%. During the nine months ended September 30, 2026 and 2025, in connection with our Series A, Series B, Series C, Series D and Series E preferred stock conversions, and the redemption of Series C Preferred Stock, we recorded deemed dividends of $28,427,000 and $31,614,000, respectively, and in connection with the adjustment in the exercise price of Series C Common Warrants, we recorded deemed dividends of $0 and $84,000, respectively. Accordingly, for the nine months ended September 30, 2026 and 2025, net loss attributable to common stockholders amounted to $31,322,000, or $0.62 per common share and $47,078,000, or $72.94 per common share, respectively.
| 37 |
Liquidity and Capital Resources
Capital Requirements
The Company has not generated any revenue from any source and the Company does not expect to generate revenue for at least the next few years. If the Company fails to complete the timely development of, or fails to obtain regulatory approval for, its product candidates, the ability of the Company to generate future revenue will be adversely affected. The Company does not know when, or if, it will generate any revenue from its product candidates and does not expect to generate revenue unless and until the Company obtains regulatory approval and commercialization of its product candidates.
The Company expects its expenses to increase significantly in connection with its ongoing activities, particularly as it continues and expands research, preclinical development, and clinical development to support marketing approval for its product candidates. In addition, if the Company obtains approval for any of its product candidates, the Company expects to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. Furthermore, the Company expects to incur additional costs associated with operating as a public company.
The Company, therefore, anticipates that substantial additional funding will be needed in connection with its continuing operations. As of September 30, 2026, the Company reported $650,681 of cash, restricted cash, and cash equivalents, a working capital deficit of approximately $19.3 million, and an accumulated deficit and stockholders’ deficit of approximately $93.7 million and $18.8 million, respectively. Additionally, during the nine months ended September 30, 2026, the Company used approximately $8.1 million of net cash in operating activities, had a net loss of approximately $2.9 million and has no revenues. During the nine months ended September 30, 2026, we received aggregate net proceeds of $7.1 million from the sale of common stock in connection with ELOC fundings and debt financings. The Company intends to devote most of the available cash to the clinical development of its product candidates and public company compliance costs.
Based on current business plans, the Company believes that the cash available as of September 30, 2026 will not fund its operations and capital requirements for one year after the date these unaudited condensed consolidated financial statements are issued. During the nine months ended September 30, 2026, we received net proceeds of $700,491 from ELOC fundings. Furthermore, during the nine months ended September 30, 2026, we issued and sold Convertible Notes for an aggregate principal amount of $5,606,500 and we received net proceeds of $4,485,200.
Additional funds are necessary to maintain current operations and to continue R&D activities. However, there can be no assurance that sufficient funding will be available to allow the Company to successfully continue its R&D activities and planned regulatory filings with the FDA. If the Company is unable to obtain the necessary funds, significant reductions in spending and the delay or cancellation of planned activities may be necessary. These actions would have a material adverse effect on the Company’s business, results of operations, and prospects. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date the unaudited consolidated financial statements are issued. These unaudited consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
Any estimate as to how long the Company expects the net proceeds from the ELOC and convertible notes payable fundings may fund the Company’s operations is based on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than its current expectations.
On October 31, 2025, the Common Stock ceased trading on Nasdaq as a result of the Panel’s delisting determination. The OTC Markets are less liquid markets for the Common Stock. Such lack of liquidity may make it more difficult for us to raise capital. Changing circumstances, some of which may be beyond the Company’s control, could result in less cash and cash equivalents available to fund operations or cause the Company to consume capital significantly faster than currently anticipated, and the Company may need to seek additional funds from additional sources sooner than planned.
Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical drug products, the Company is unable to estimate the exact amount of its operating capital requirements. The Company’s future funding requirements will depend on many factors, including, but not limited to those listed under “Factors Affecting Our Performance” above.
Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete, and the Company may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, the Company’s product candidates, if approved, may not achieve commercial success. Commercial revenues, if any, will be derived from sales of product candidates that the Company does not expect to be commercially available in the near term, if at all. Accordingly, the Company will need to continue to rely on additional financing to achieve its business objectives. Adequate additional financing may not be available to the Company on acceptable terms, or at all. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the terms of these equity securities or this debt may restrict the Company’s ability to operate. Any future debt financing and equity financing, if available, may involve covenants limiting and restricting the ability to take specific actions, such as incurring additional debt, making capital expenditures, entering into profit-sharing or other arrangements or declaring dividends. If the Company raises additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, it may be required to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to the Company. If the Company is unable to raise capital when needed or on acceptable terms, the Company could be forced to delay, reduce or eliminate its R&D programs or future commercialization efforts.
| 38 |
Cash Flows
| For the Nine Months Ended September 30, | ||||||||||||
| 2026 | 2025 | Change | ||||||||||
| Net cash used in operating activities | $ | (8,122,990 | ) | $ | (12,273,817 | ) | $ | 4,150,827 | ||||
| Net cash provided by investing activities | - | 500,000 | (500,000 | ) | ||||||||
| Net cash provided by financing activities | 7,111,291 | 10,468,829 | (3,357,538 | ) | ||||||||
| Net decrease in cash, restricted cash, and cash equivalents | $ | (1,011,699 | ) | $ | (1,304,988 | ) | $ | 293,289 | ||||
Net cash used in operating activities
Net cash used in operating activities for the nine months ended September 30, 2026 primarily reflected a net loss of $2,896,000, adjusted for the reconciliation of non-cash items such as depreciation expense of $175,000, stock-based compensation of $2,861,000, amortization of right-of-use asset of $686,000, amortization of debt discount of $1,562,000, gain on reevaluation of preferred stock liabilities of $10,335,000, a gain on debt extinguishment of $3,801,000, and loss on initial and reevaluation of derivative liabilities of $3,396,000, and changes in operating asset and liabilities primarily consisting of a decrease in prepaid expenses and other current assets of $628,000, an increase in accounts payable of $525,000, an increase in accrued liabilities of $152,000, a decrease in insurance financing liability of $332,000, and a decrease in operating lease liabilities of $723,000.
Net cash used in operating activities for the nine months ended September 30, 2025 primarily reflected a net loss of $15,380,000, adjusted for the reconciliation of non-cash items such as depreciation expense of $215,000, stock-based compensation of $836,000, stock-based inducement expense of $864,000, write off of deferred offering costs of $500,000, and amortization of right-of-use asset of $595,000, and changes in operating asset and liabilities primarily consisting of an increase in prepaid expenses and other current assets of $257,000, an increase in accounts payable of $1,426,000, a decrease in accrued liabilities of $429,000, and a decrease in operating lease liabilities of $644,000.
Net cash provided by investing activities
Net cash provided by investing activities for the nine months ended September 30, 2025 amounted to $500,000. During the nine months ended September 30, 2025, we received $500,000 from the sale of equity securities. We did not have any investing activities during the nine months ended September 30, 2026.
Net cash provided by financing activities
Net cash provided by financing activities for the nine months ended September 30, 2026 amounted to $7,111,000 as compared to $10,469,000 for the nine months ended September 30, 2025.
During the nine months ended September 30, 2026, net cash provided by financing activities of $7,111,000 was primarily attributable to the receipt of net proceeds of $700,000 from the sale of Common Stock under the ELOC, net proceeds of $4,485,000 from the sale of convertible notes payable, and net proceeds $1,926,000 from advances received under the Consolidated Note from SRX.
During the nine months ended September 30, 2025, net cash provided by financing activities of $10,469,000 was primarily attributable to the receipt of net proceeds of $500,000 from the exercise of Series A Preferred Warrants, net proceeds of $3,704,000 from the sale of common stock under the ELOC and collection of stock subscription receivables, net proceeds of $2,561,000 from the sale of Series D Preferred Stock, and net proceeds from sale of common stock and pre-funded warrants of $4,273,000, offset by the cash redemption of Series C Preferred Stock of $395,000 and the payment of offering costs of $174,000.
Critical Accounting Estimates
During the nine months ended September 30, 2026, there were no material changes to our critical accounting policies from those described in our Annual Report on Form 10-K filed with the SEC on April 15, 2026, except as follow:
Derivative financial instruments – The Company evaluates financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. Derivative instruments are initially recorded at fair value on the grant date and re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. Derivative assets and liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
| 39 |
Preferred stock liabilities – In May 2026, as a result of the issuance of additional convertible promissory notes and the reduction of preferred stock conversion prices from $0.05 to $0.01, the Company determined that it no longer had sufficient authorized but unissued shares of common stock to settle all outstanding potentially dilutive instruments upon conversion or exercise.
Under ASC 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity, a contract may be classified in equity only if the Company has sufficient authorized and unissued shares to settle it. When authorized shares are insufficient, the Company determines which instruments to reclassify using a sequencing policy based on the latest inception date. Under this policy, instruments with the most recent inception dates are reclassified first. Applying this policy, the Company determined that its Series D and Series E Convertible Preferred Stock no longer qualified for equity classification. During the three months ended June 30, 2026, the Company reclassified these instruments from stockholders’ equity to preferred stock liabilities at their fair value on that date of $21,584,122. Of this amount, $8,784,862 related to the Series D Convertible Preferred Stock and $12,799,260 to the Series E Convertible Preferred Stock.
Preferred stock liabilities are measured at fair value at each reporting date and immediately before reclassification or conversion. Changes in fair value are recognized in the consolidated statements of operations. The Company estimates fair value using an as-if-converted approach. This approach multiplies the number of common shares issuable upon conversion by the quoted closing price of the Company’s common stock on the measurement date. The number of shares issuable is derived from the $1,000 stated value per share and the conversion price in effect on the measurement date. Because these inputs are observable, the measurement is classified as Level 2 in the fair value hierarchy.
Following this transaction, the Company has no convertible debt outstanding. The Company reassessed the classification of its preferred stock under its sequencing policy. It determined that sufficient authorized shares are now available to settle the Series D Convertible Preferred Stock, but not the Series E Convertible Preferred Stock. Accordingly, on August 27, 2026, the Company remeasured the Series D Convertible Preferred Stock to its fair value of $7,322,990 and reclassified it from preferred stock liabilities to stockholders’ equity. Gains and losses recognized before the reclassification were not reversed. The Series E Convertible Preferred Stock remains classified as a preferred stock liability as of September 30, 2026. It will continue to be remeasured at fair value until the Company has sufficient authorized shares to settle it, or until it is converted or otherwise settled.
Recent Accounting Standards
See the section titled in Note 2 to the Company’s unaudited consolidated financial statements for the nine months ended September 30, 2026, appearing elsewhere herein.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
As a smaller reporting company defined by Rule 12b-2 of the Securities Exchange Act of 1934, we are not required to provide the information required by this Item.
Item 4. Controls and Procedures
Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Evaluation of Disclosure Controls and Procedures
The Company’s Principal Executive Officer and Principal Financial Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended. Based on this evaluation, the certifying officers concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were not effective due to the existence of material weaknesses in internal control over financial reporting.
Material Weaknesses Identified
The material weaknesses identified include:
| ● | We currently lack multiple levels of management review on complex business, accounting, and financial reporting issues; and |
| ● | We currently lack adequate segregation of duties as a result of our limited financial resources to support hiring of personnel. |
However, we do not believe the material weaknesses described above caused any significant misreporting of our consolidated financial condition and results of operations for the three months ended September 30, 2026.
Remediation Plan
Due to a lack of working capital in 2025 and 2024 and during the nine months ended September 30, 2026, we were not and are not able to implement a remediation plan in the foreseeable future. We plan on implementing policies and procedures to address and mitigate all material weaknesses if we receive additional funding and are able to expand our accounting staff.
We are committed to the improvement of our internal control processes and will continue to review our financial reporting controls and procedures diligently and vigorously. As we continue to evaluate and work to improve our internal control over financial reporting, we may determine to take additional measures to address control deficiencies.
Changes in Internal Control Over Financial Reporting
During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
| 40 |
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of September 30, 2026, we do not believe we are party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Item 1A. Risk Factors
Except as set forth below, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on April 15, 2026. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.
The issuance of shares of our Common Stock upon conversion or exercise of our outstanding Series A Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, and other securities that we may issue in future financing transactions may result in substantial dilution to our stockholders.
As of November 14, 2026, the Company currently has outstanding: (i) 83,309,742 shares of Common Stock, (ii) 1,429 shares of Series A Preferred Stock with a stated value of approximately $1.4 million, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a current effective conversion price of $0.01 per share; (iii) 7 shares of Series C Preferred Stock with a stated value of $7,000, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a conversion price of $0.01 per share; (iv) 5,192 shares of Series D Preferred Stock with a stated value of approximately $5.2 million, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a current effective conversion price of $0.01 per share, (v) 3,552 shares of Series E Preferred Stock with a stated value of approximately $3.6 million, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a current effective conversion price of $0.01 per share; and (vi) 159,724 warrants to purchase 159,727 shares of Common Stock at an weighted average exercise piece of $707.39.
The terms of the Series A Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock and the Series E Preferred Stock contain certain penalties and adjustments to the amount included in determination of the conversion rate following certain breaches of the Company’s obligations thereunder, including, among other things, as a result of a failure to file or cause the SEC to declare one or more registration statements relating to the resale of the shares of Common Stock issuable upon conversion thereof by specified deadlines, certain defaults under indebtedness of the Company or judgments against the Company and failure to deliver shares of Common Stock upon conversion in a timely manner. For example, the penalties and adjustments include a 25% premium added to the stated value for determining the conversion rate in connection with breaches other than the breach of the requirement to redeem the shares of Series A Preferred Stock by August 31, 2025, which resulted in a 50% premium, and the addition to the stated value of an amount equal to the value of the shares of Common Stock into which the Series A Preferred Stock would have been convertible if the conversion price were equal to 80% of the lowest volume weighted average price during the five trading days immediately prior to conversion. Such penalties and adjustments, which applied during the period when substantially all of the conversions since the Business Combination occurred as a result of a failure to file and cause the SEC to declare a registration statement with respect to the resale of the underlying shares in a timely manner, have resulted and may in the future result in the issuance of shares of Common Stock at an effective conversion price below the trading price of our Common Stock at the time of such conversion.
We cannot assure you that we will remain in compliance with all of the terms of the Series A Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock and that such penalties and adjustments will not apply in the future. In addition, we cannot assure you that we will not issue additional convertible or other derivative securities with highly dilutive penalty or adjustment provisions. As described elsewhere in this Quarterly Report, the Company needs to obtain financing to fund its research and development activities and clinical trials, as well as other operations. Under challenging conditions in the equity capital markets, particularly for pre-commercialization biotech companies, we may have no viable alternatives to agreeing to inclusion of such provisions in the terms of future financings.
The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown and may adversely affect our business model.
Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.
There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. For more information, see the section of titled “Business – Healthcare Laws and Regulations – Healthcare Reform” in the Annual Report on Form 10-K for the year ended December 31, 2025.
For example, the Medicare Drug Price Negotiation Program, administered by CMS as part of the Inflation Reduction Act of 2022, commonly referred to as the IRA, may apply to our products if they are selected for negotiation, which could materially reduce the amount of revenue we can generate from our products if they are approved. Prior to the enactment of the One Big Beautiful Bill Act of 2025 (“OBBBA”), orphan drugs were exempt from Medicare price negotiation under the IRA only if they had received a single orphan designation and were approved solely for the corresponding rare disease or condition. The OBBBA amended this exemption to apply more broadly: now, any orphan-designated drug is exempt from price negotiation, regardless of the number of orphan designations it has received, provided the drug’s approved indications are exclusively for those rare diseases. The OBBBA also included significant reforms to Medicaid, including an estimated $1 trillion in reduced federal Medicaid spending from 2025 through 2034, the imposition of work requirements for certain adult enrollees, more frequent eligibility redeterminations, and increased cost-sharing for beneficiaries. These changes are expected to reduce overall Medicaid enrollment and access to care. Although the effect on our future product candidates or business is unknown, any decrease in the number of insured patients or reimbursement levels for our products could adversely affect our potential for revenue and our commercial prospects.
| 41 |
In addition, multiple executive actions in the first half of 2025 signal the federal government’s increasing focus on lowering prescription drug prices, adding to the uncertainty surrounding future drug pricing and reimbursement frameworks. For example:
| ● | On May 12, 2025, President Trump signed the executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing,” which directs the Secretary of Health and Human Services (“HHS”) to identify and communicate most-favored-nation price targets for prescription drugs and to propose a rulemaking plan to impose such pricing if “significant progress” is not made. The order also directs the federal government to explore regulatory pathways that would facilitate direct-to-patient sales for manufacturers that meet these price targets. Additionally, it signals potential further action against manufacturers that fail to offer most-favored-nation pricing, including evaluating whether to modify or rescind marketing approvals or allow individual drug importation waivers. In July 2025, President Trump sent letters to pharmaceutical companies demanding further reduced prices more in line with most-favored-nation pricing. On September 30, 2025, the White House announced the first MFN agreement (Pfizer), and reports indicate additional negotiations are ongoing. The scope, timing, and ultimate impact of any further actions or agreements remain uncertain. Further, in September and October 2025, multiple drug manufacturers announced plans to, for certain of their drugs, lower prices to reflect similar pricing around the world, and to sell these reduced-price drugs on a direct-to-consumer purchasing platform that is yet to be developed by the federal government. |
| ● | By the end of 2025, 16 major pharmaceutical manufacturers had entered into voluntary MFN pricing agreements with the Administration, committing to offer MFN-aligned pricing to state Medicaid programs and to sell certain products at discounted prices through TrumpRx.gov, a federally operated direct-to-consumer prescription drug platform that launched on February 5, 2026. On November 6, 2025, CMS announced the GENEROUS Model, a voluntary five-year CMMI initiative under which participating manufacturers would pay supplemental rebates to state Medicaid programs benchmarked to international pricing in eight reference countries; the manufacturer application deadline has been extended to April 30, 2026. On December 19, 2025, CMS published two proposed rules (the GLOBE Model (Medicare Part B) and GUARD Model (Medicare Part D)) which would impose mandatory MFN-based rebates on manufacturers of qualifying high-cost single-source drugs, calculated using international pricing data from 19 OECD reference countries and applied to approximately 25% of Medicare beneficiaries in randomly selected geographic areas. The GLOBE Model performance period would begin October 1, 2026; GUARD would begin January 1, 2027. The 60-day public comment period for both proposed rules closed on February 23, 2026. Prior efforts to implement MFN pricing during President Trump’s first term were enjoined by federal courts, and industry commentators widely anticipate legal challenges to the current proposals. If finalized and implemented, these models could materially affect the pricing, reimbursement, and commercial viability of our product candidates in the United States, including by linking U.S. reimbursement to prices established in foreign markets over which we may have limited control. |
| ● | Previously, on April 15, 2025, President Trump issued the executive order “Lowering Drug Prices by Once Again Putting Americans First,” which contains a broad set of directives aimed at reducing drug costs. Among other actions, the order directs HHS to revise guidance under the Inflation Reduction Act (“IRA”) to eliminate the so-called “pill penalty,” which currently subjects small molecule drugs to Medicare price negotiation four years earlier than biologics. The order also calls for a comprehensive evaluation of the role played by pharmacy benefit managers (“PBMs”) in drug pricing and market access. |
The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:
| ● | the demand for our product candidates, if we obtain regulatory approval; |
| ● | our ability to set a price that we believe is fair for our products; |
| ● | our ability to obtain coverage and reimbursement approval for a product; |
| ● | our ability to generate revenue and achieve or maintain profitability; |
| ● | the level of taxes that we are required to pay; and |
| ● | the availability of capital. |
Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Director and Officer Trading Arrangements
From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). None of our directors or “officers,” as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934,
| 42 |
Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
| 43 |
| * | Filed herewith. |
| † | Certain portions of this document that constitute confidential information have been redacted pursuant to Item 601(b)(10) of Regulation S-K. |
| # | The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this report and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference. |
| 44 |
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CERO THERAPEUTICS HOLDINGS, INC. | ||
| Date: November 13, 2026 | By: | /s/ Chris Ehrlich |
| Name: | Chris Ehrlich | |
| Title: | Chairman and Chief Executive Officer | |
| (Principal Executive Officer) | ||
| Date: November 13, 2026 | By: | /s/ Andrew Kucharchuk |
| Name: | Andrew Kucharchuk | |
| Title: | Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | ||
| 45 |